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Allergic asthma is a significant medical issue, affecting more than 300 million individuals 
and causing approximately 250,000 deaths each year. Current asthma therapies 
temporarily minimize discomfort and manage symptoms, but there are no effective long-
term, preventative, or curative agents available. Recent studies have indicated that 
targeting immunogens to specific immune cells via fusion with cytokines increases the 
effectiveness of immunotherapy in animal models for asthma as well as other immune-
mediated disease models such as experimental autoimmune encephalomyelitis. This 
study tested the hypothesis that fusion proteins comprised of granulocyte macrophage 
colony stimulating factor (GM-CSF) and OVA 323-339 epitopes potentiate antigen-
specific immunological tolerance and attenuate development of pulmonary 
inflammation. Fusion products were generated through combining OVA 323-339 and 
GM-CSF sequences, and biological activity of fusion protein cytokine and antigenic 
domains was assessed. A successful model of ovalbumin-induced inflammation in mice 
was then established for verification of cytokine fusion protein vaccine efficacy. In the 
model, pre-treatment with the cytokine fusion protein vaccine was tested for ability to 
attenuate OVA-induced increases in inflammation. GMCSF-OVA 323-339-treated mice 
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showed significantly decreased numbers of pro-inflammatory eosinophils, neutrophils, 
and lymphocytes, and cellular infiltration in perivascular, peribronchial, peribronchiolar, 
and parenchymal spaces were visibly lessened. In addition, small airway mucus 
deposition was reduced in mice given the fusion protein. In this study, it was found that 
pre-treatment of mice with GMCSF-OVA 323-339 fusion proteins reduced pulmonary 
inflammation when compared to mice given saline treatment, demonstrating that 
GMCSF-OVA 323-339 fusion proteins have the capability of influencing immune 
responses within a murine model of pulmonary inflammation. Data from this study 
suggests potential for cytokine-fusion proteins as a therapeutic tool in pathological 
pulmonary inflammation as well as in other fields involving immune system-mediated 
pathologies.   
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CHAPTER 1: INTRODUCTION 
 
Allergic Asthma 
Allergic asthma, also known as atopic asthma, is a significant medical problem, 
affecting more than 300 million individuals (over 20 million US) and causing 
approximately 250,000 deaths (~3,500 US) every year (Global surveillance, prevention 
and control of chronic respiratory diseases: A comprehensive approach. 2007; Heron et 
al., 2009). Allergic asthma is the most prevalent form of asthma, accounting for more 
than 50% of those afflicted with the condition (Asthma at a glance. 1999). Asthma is an 
immune-mediated chronic disease marked by airway inflammation, obstruction, and 
hyperresponsiveness to any of a variety of normally innocuous stimuli, leading to 
respiratory difficulty and possible complications for allergic asthma patients. Current 
asthma therapies temporarily minimize discomfort and manage symptoms, but there are 
no effective long-term, preventative, or curative agents available. New methods or 
compounds for treating allergic asthma are a necessity. 
Asthma Pathogenesis 
 Asthma pathogenesis is the result of an inappropriate immune response to a 
typically innocuous immunogen. Inhaled aeroallergens are processed via the major 
histocompatibility complex (MHC) class II pathway, and are internalized by antigen 
presenting cells (APCs) via endocytosis. Vesicles containing the aeroallergen are then 
transported to lysosomes for degradation, and as vesicles approach the lysosome, 
vesicle pH lowers, aiding in degradation of the antigen. In the endosomal compartment, 
MHC class II (MHC-II) molecules come into contact with degraded antigen and bind 
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fragments 13-18 amino acids in length, transporting them to the cell surface. MHC-II 
bound to antigen at the cell surface can then be recognized by CD4+ T cells, that, in the 
event of recognition and subsequent activation, will activate T helper (TH) 2 cells 
(Janeway and Travers, 1997). TH2 cells will then differentiate into IL-4, IL-5, and IL-13 
secretory cells, leading to increases in B cell IgE synthesis, mast cell activation via 
cross-linking of cell surface FcεRI by IgE and antigen, and the subsequent release of 
histamine, prostaglandins, and leukotrienes (Busse and Lemanske R.F., 2007). Upon 
release, these factors have the capacity to interact directly with bronchial smooth 
muscle, giving rise to an acute, early phase allergic response (EAR) characterized by 
bronchoconstriction, airway edema, and mucus hypersecretion, resulting in wheezing, 
airway hyperresponsiveness, and reduced forced expiratory volume in one second 
(FEV1). The EAR may be present for 30 minutes to 2 hours, although in rare acute 
episodes, anaphylaxis, a severe and potentially life-threatening reaction, may occur 
within seconds or minutes. For nearly 60% of asthmatics, EAR is followed 
approximately 2 hours later by a late phase allergic response (LAR) that may persist for 
days. The LAR is due the migration and accumulation of inflammatory immune cells in 
the airways and the further release of inflammatory mediators. Accumulation of 
neutrophils and lymphocytes are highest within 24 hours of contact with the antigen, 
and accumulation of eosinophils is increased by 48 hours (Lommatzsch et al., 2006). 
LAR is characterized by bronchoconstriction and further wheezing due to airway 
hyperresponsiveness and reactivity to the released inflammatory mediators (Berend et 
al., 2008).   
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It is generally thought that allergic asthma results from imbalanced immune 
system TH1/TH2 responses, leading to a system that favors TH2 interactions. The 
concept that such an imbalance could lead to asthma pathogenesis has roots in the TH2 
hypothesis, which suggests that in balanced systems, CD3+ CD4+ lymphocytes 
differentiate into either TH1 or TH2 cells, and that TH1 and TH2 cells reciprocally inhibit 
the differentiation of one another through IFN-γ and IL-4, respectively (Coffman, 2006). 
This is not to say, however, that TH1 cells and cytokines do not contribute to allergic 
asthma. There is extensive overlap and redundancy inherent in the complex cell and 
cytokine networks contributing to asthmatic immunopathology, and the intricacies of 
these networks are central to the understanding of asthma pathogenesis and potential 
future therapeutic targets. 
Cell Network  
Various cell types participate in allergic asthma pathogenesis. Some of the key 
participants in the generation of the response generally include dendritic cells, T helper 
lymphocytes, Cytotoxic T-lymphocytes, Memory lymphocytes, Type 1 Natural Killer T-
lymphocytes, Natural Killer cells, and γδ T cells, while T regulatory lymphocytes (TRegs) 
aid in the balance and suppression of the response. These cell types can then exert 
effects on smooth muscle cells, eosinophils, goblet cells, mast cells, B cells, and 
neutrophils, cell types that are responsible for the mucus production, AHR (airway 
hyperresponsiveness), and inflammation seen in asthma. The actions of each particular 
cell type and the interactions between them within the asthmatic cell network underlie 
the inflammation and pathogenesis observed in allergic asthma (figure 1.1).  
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Figure 1.1 Overview of cell types involved in asthma pathogenesis 
Multiple cell types participate in allergen-mediated pathogenesis. Some of the key 
participants in the initiation of the response include dendritic cells and various T cell 
subsets. Cytokines and other mediators from these cells can, in turn, act upon various 
other cell types, resulting in the further release of pro-inflammatory mediators. 
Interactions between these cells and their mediators contribute to the mucus production, 
AHR, and inflammation seen in asthma. 
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Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews Immunology] 
(Lloyd, C.M.; Hessel, E.H. Functions of T cells in asthma: more than just TH2 cells. 
Nature Reviews Immunology, 2010. 10, 838-848). Copyright 2010. 
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Dendritic Cells 
 DCs are considered one of the few “professional” antigen presenting cells due to 
high efficiency in the up-take and presentation of antigen. Typically, DCs found in 
peripheral tissues are in an immature state, characterized by fewer T-cell activating 
costimulatory molecules as well as less efficient antigen presentation capabilities. 
Immature DCs undergo maturation upon activation, and the activation signals dictate 
DC responses and subsequent polarization toward TH1, TH2, TH9, TH17, or TReg 
responses. This process begins with extracellular peptides presented on the cell surface 
of DCs within the peptide binding groove of MHC-II molecules and as a unit, may lead 
to recognition by T cell receptors. Upon recognition, T cells synthesize and express 
CD40 ligand, connecting with CD40 on the surface of DCs, resulting in the DC synthesis 
of B7 costimulatory molecules, ligands for T cell CD28 receptors. Proper costimulatory 
signaling induces the production of IL-2 and, in allergic asthma, TH2 cell proliferation. 
TH2 cells may then secrete a number of cytokines such as IL-4, IL-5, and IL-13 to 
activate other immune cell types, resulting in an inflammatory cascade. Secretion of IL-4 
contributes to immunoglobulin class switching from IgM to IgE in B cells, and the 
production of high-affinity IgE antibody to the antigen. IgE then complexes with FcεRI 
receptors on mast cells, inducing histamine release when crosslinked by antigen. IL-5 
secretion increases eosinophil migration, activation, and survival and IL-13 secretion 
contributes to mucus secretion and airway hypersensitivity (Steinman and Hemmi, 
2006; Chung and Barnes, 1999). While DCs are clearly one of the cell types involved in 
the initial stages of an allergic reaction, it should be noted that not all DC subsets are 
proinflammatory. Some subsets induce tolerance to antigen and decrease inflammatory 
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immune responses. Conventional DCs (cDC) and inflammatory DCs likely play a role in 
the asthmatic allergic responses while plasmacytoid (pDC) are capable of anti-
inflammatory roles. cDCs in the conducting airways can project dendrites through 
bronchial epithelial cell tight junctions for the detection of inspired antigen, and within 
the lamina propria expression of SIRPα and production of chemokines such as CCL17 
and CCL22 can aid in DC migration and recruitment (Hammad and Lambrecht, 2011; 
Hammad et al., 2010). pDCs, found in alveolar septa and large conducting airways on 
the other hand, may mediate anti-inflammatory responses through the expression of 
programmed death ligand 1 (PD-L1), which, when highly expressed on pDCs, has been 
correlated with elevated TReg numbers (Hammad and Lambrecht, 2011; Kool et al., 
2009). DC phenotype can be determined by a number of factors, including the cytokine 
milieu. Fms-like tyrosine kinase receptor 3-ligand (Flt3L) has been shown to contribute 
to CD8a+ and CD8a- DCs and a skewed T cell response toward a TH1 reaction while 
GM-CSF has been shown to contribute toward a pro-inflammatory phenotype that 
interestingly, does not counteract resolving inflammation, as well as a tolerogenic 
CD8a- phenotype that has been implicated in tolerance (Cheatem et al., 2009; 
Blyszczuk et al., 2013). 
T-helper lymphocytes 
Exposure to antigen can induce naïve CD4+ T-cell differentiation into effector cell 
TH1, TH2, TH9, TH17, or TReg phenotypes, some undergoing further differentiation into 
memory cells that reactivate rapidly upon antigen re-exposure. While TH2 effector cells 
have been heavily implicated in asthma pathogenesis, other TH subsets contribute as 
well and depending on the level of involvement, can give rise to various asthma 
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phenotypes (such as neutrophilic versus eosinophilic asthmatic inflammation, for 
example) (Lees and Farber, 2010; Thorburn and Hansbro, 2010; Lloyd and Saglani, 
2013).  
While TH1 and TH2 cells both develop from naïve CD4+ T cells, each subset 
reciprocally inhibits the growth of the other due to the release of opposing cytokine 
factors, particularly IFN-γ and IL-4, respectively (Coffman, 2006). In studies with mice 
lacking T-bet (T-box expressed in T cells), a transcription factor central to IFN-γ 
expression, mice spontaneously developed classic asthma symptoms. Mice lacking 
GATA-3, a transcription factor important to TH2 differentiation, did not develop 
inflammation or AHR in an asthma model (Robinson, 2010). There is overlap and 
redundancy in the system, however, and although TH2 cells have been implicated as 
the major players in the asthmatic response, there are studies that suggest a role for 
their TH1 counterparts as well. It has been found, for instance, that adoptive transfer of 
TH1 cells has caused mucosal eosinophilia in Brown Norway rats and increased 
neutrophils in mouse BAL (Huang et al., 2001). 
TH9 cells have been shown to develop from CD4+ T cells in the presence of IL-4 
and TGF-β. Following house dust mite exposure in murine studies, differentiation and 
proliferation of IL-9-secreting T cells occurred quickly, even more so than for TH2 cells. 
In addition, TH9 cell adoptive transfer caused inflammatory alterations, specifically with 
regard to increased mast cell recruitment and activation. In human studies, TH9 cells 
were elevated in the peripheral blood of asthmatic patients, and TH9 elevation showed a 
positive correlation with patient IgE (Thorburn and Hansbro, 2010). An anti-IL-9 
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antibody, MEDI-528, had modest results in early clinical trials, and further study with the 
drug continues (Antoniu, 2010a). 
TH17 cells can develop from naïve CD4+ T cells in the presence of IL-23. They 
may also develop in the presence of IL-6 and TGF-β, although in the absence of IL-6, 
TRegs are generated from the precursor cells instead of TH17 cells (Thorburn and 
Hansbro, 2010; Robinson, 2010). The combination of IL-6 and TGF-β acts through 
transcription factors Smad2/3, STAT3, and NF-κB to induce IL-17 expression and TH17 
cell development (Lloyd and Saglani, 2013). TH17 cells have been shown to secrete key 
asthma cytokines IL-4, IL-5, and IL-13 following exposure to high IL-4 levels, and in 
mouse studies, have been shown to induce neutrophilic (rather than eosinophilic) 
airway inflammation, AHR, and enhanced TH2 responses (Lloyd and Saglani, 2013; 
Robinson, 2010; Cosmi et al., 2010). TH17 cells were further linked to AHR in a study in 
mice with a defective Dendritic Cell αvβ8 integrin; mice with the defective integrin had 
no TH17 cells in the lungs after antigen challenge, and a lack of airway narrowing and 
AHR. In addition, TH17 cytokines have the capacity to act directly on airway smooth 
muscle (Lloyd and Saglani, 2013). While these studies suggest that blockade of IL-17 
may be protective during sensitization phases, other studies have shown that treatment 
with IL-17A during antigen re-challenge has a protective effect, and that IL-17-secreting 
γδ T cells are capable of decreasing inflammation and remodeling in murine models. 
Together, these studies suggest that the timing of IL-17 secretion with respect to 
disease progression is an important consideration (Lloyd and Saglani, 2013). 
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T-regulatory lymphocytes 
CD4+ CD25+ T-regulatory lymphocytes, or TRegs, are immunosuppressive and 
may develop naturally in the thymus following exposure to self-antigens (natural TRegs), 
or may be induced from CD4+ cells in the presence of IL-2 and TGF-β (induced TRegs) 
(Thorburn and Hansbro, 2010). In addition to having the potential of being induced from 
CD4+ cells, recent observations have shown that TRegs have the ability to then 
differentiate into other effector cell subsets, suggesting that TRegs have great plasticity. 
Both natural and induced phenotypes are important in maintaining immune system 
balance, though FoxP3 (implicated in TReg suppressive activity, stability, and survival), 
which is present on most natural regulatory T cells, may or may not be expressed in 
induced TRegs as both FoxP3+ and FoxP3- populations have been observed (Thorburn 
and Hansbro, 2010).   
TRegs exert immunosuppressive effects in various ways, including the release of 
anti-inflammatory cytokines such as IL-10 and TGF-β, through cell-contact mediated 
mechanisms leading to T effector cell cycle arrest or apoptosis or APC immaturity, as 
well as through competing for T effector cell growth factors such as IL-2. Human 
asthmatics have been shown to have fewer TRegs in the blood and in BAL fluid, and for 
the TRegs that are present, the response to chemokines regulating migration to the 
airways is mitigated (Vock et al., 2010). A few studies have shown an increase in TRegs 
in severe asthmatics, although these increases may be due to induced TRegs generated 
in an unsuccessful effort to combat overwhelming inflammation (Thorburn and Hansbro, 
2010). 
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Cytotoxic T-lymphocytes 
CD8+ cytotoxic T-lymphocytes respond to antigen presented on MHC Class I 
and are classified by subsets resembling those for CD4+ cells: Tc1, Tc2, Tc17, FoxP3+, 
γδ+, and effector and memory subsets (Betts and Kemeny, 2009). Each subset has the 
capacity to produce different cytokines, some TH1-oriented and others TH2-oriented, and 
thus may be pro-inflammatory or anti-inflammatory depending on the dominant subset. 
Some murine studies have observed that virus-activated CD8+ cells, when in the 
presence of IL-4, can produce IL-4, IL-5, and IL-10, as well as provide B-cell support, 
showing a means by which viral infection may potentiate asthmatic episodes (Coyle et 
al., 1995). Other studies have shown that memory CD8+ T cells may undergo 
nonspecific activation when exposed to IL-12 and IL-18, causing proliferation and 
production of IFN-γ and TNF-α, which may regulate or dampen TH2 responses 
(Robinson, 2010). 
Memory lymphocytes 
Memory lymphocytes, key components of the acquired immune response, are 
antigen-specific and are developed after exposure and recognition of a particular 
antigen. They may be T or B cell-derived and are long-lived to provide rapid protection 
upon re-exposure to the antigen due to enhanced function and lower activation 
threshold. Memory T cells may be central memory (TCM) or effector memory (TEM), 
depending on CD62L and CCR7 expression, receptors allowing migration into high 
endothelial venules and so, the lymph nodes. Memory cells may also be CD4+ or CD8+ 
(Kaech et al., 2002; Sallusto et al., 2004; Zielinski et al., 2011). 
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TCM express high levels of CD62L and CCR7, tend to be found in the lymph 
nodes and tonsils, and have higher proliferative ability than the CD62L- and CCR7-low 
TEM, which tend to be found in the lungs, gut, and liver and have more potent effector 
function (Sallusto et al., 2004). Studies have shown that the TCM and TEM phenotypes 
may be flexible, however, as each phenotype has been observed to convert to the 
other; some TCM resulting from TCM proliferation and expansion have been shown to 
convert to TEM cell types, and TEM have been shown to convert to TCM following CD4 or 
CD8 T cell activation (Lees and Farber, 2010). Both TCM and TEM may be either CD4+ or 
CD8+, although the TCM phenotype is more common in the CD4+ subset while the TEM 
phenotype is more common in the CD8+ subset (Sallusto et al., 2004).  
γδ T-lymphocytes 
γδ T-lymphocytes have T cell receptors composed of γ and δ chains rather than 
the α and β chains found in most CD4+ T cell receptors, and interact with lipid antigens 
such as pollen-derived phospholipids through receptor CD1d. TH2-cytokine-secreting γδ 
T-lymphocytes have been observed in higher numbers in the airways and 
bronchoalveolar lavage fluid of asthmatic patients compared to normal controls, 
suggesting a role for γδ T-cells in asthma (Lloyd and Saglani, 2013; Robinson, 2010; 
Afshar et al., 2008). The role of γδ T-lymphocytes may be two-fold, however, depending 
on the dominant subtype present in the airways (Lloyd and Hessel, 2010; Spinozzi and 
Porcelli, 2007). Vγ1+ γδ T-lymphocytes secrete IL-5 and IL-13, contributing to 
eosinophilia and AHR while Vγ4+ γδ T-lymphocytes secrete IL-17A, which may inhibit 
inflammation if present during an antigen re-challenge (Lloyd and Saglani, 2013; Afshar 
et al., 2008; Murdoch and Lloyd, 2010). 
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Type 1 Natural Killer T-lymphocytes 
Type 1, or invariant, Natural Killer T-lymphocytes (iNKT) account for 2 - 10% of 
the T-lymphocyte population (0.2 - 1% of the total white cells) in asthmatic airways. 
iNKT cells express a highly-restricted αβ T-cell repertoire with an invariant α chain that 
is only capable of interacting with CD1d bound to antigen. CD1d presents glycolipid 
antigen, and can promote secretion of IL-4, IL-5, IL-9, IL-13 and IFN-γ by iNKT cells 
(Meyer et al., 2008; Iwamura and Nakayama, 2010). iNKT cells also respond and 
become activated in the presence of IL-25 and IL-33, cytokines released by epithelial 
cells due to cell injury (Bartemes and Kita, 2012; Watarai et al., 2012). 
IL-13 secretion due to iNKT cell activation stimulates macrophage production of 
IL-13, resulting in further autocrine-enhanced IL-13 production (Holtzman et al., 2009). 
Several studies have shown the presence of iNKT cells as a necessity for AHR 
induction. CD1d-/- mice, which lack iNKT cells, could not develop AHR after 
sensitization and challenge, nor could Jα18-/- mice, which lack the Type 1 iNKT cell 
receptor invariant α chain. In addition, Jα18-/- mice had fewer eosinophils post 
sensitization and challenge. Following adoptive transfer of functional wild-type iNKT into 
Jα18-/- mice, however, allowed for induction of AHR. It is thought that perhaps, under 
inflammatory conditions elicited by asthma pathogenesis, ensuing cellular alterations 
allow for the presentation of endogenous glycolipids and subsequent iNKT cell 
activation (Meyer et al., 2008). 
Unlike most TH2 cells, iNKT cells are resistant to corticosteroids, a common 
means of treating asthmatic inflammation. This is important in light of the fact that 10-
30% of asthmatics have corticosteroid-resistant asthma. Also of note is that the majority 
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of patients with severe asthma are corticosteroid-resistant asthma cases, and that 
corticosteroid-resistant asthma contributes to a large number of asthma-related deaths 
(Meyer et al., 2008). 
Natural Killer (NK) cells 
NK T cells account for approximately 10% of lymphocytes in circulation. They are 
a glycolipid-responsive T cell subset that can process and present antigen to TH2 cells 
via MHC Class II (Hanna et al., 2004). NK T cells heavily secrete TH2 cytokines, 
although they may secrete TH1 cytokines as well (Thorburn and Hansbro, 2010; Moretta 
et al., 2006). These cells have been seen in higher numbers in the sinus mucosa and 
sputum of asthmatic patients, and studies in laboratory animals suggest a necessity for 
NK T cells in AHR development. Noteworthy is that the cytotoxicity of NK T cells 
extends to TRegs in asthmatic individuals, a phenomenon which is not observed in 
healthy controls, perhaps partly explaining the drop in TReg numbers in asthmatic 
individuals (Thorburn and Hansbro, 2010). 
In a study examining the role of NK cells in mouse models of allergic asthma, NK 
cells were found to augment eosinophil numbers, while in another, eosinophilic 
inflammation, AHR, and goblet cell proliferation was attenuated through NK cell effects 
(Korsgren et al., 1999; Matsubara et al., 2007). Yet another study showed that NK cells 
played a role in the resolution of inflammation in a murine asthma model (Haworth et al., 
2011). It is possible that the different roles of the NK cell in these studies were due to 
differences in the NK subsets. 
NK cells may be CD56bright or CD56dim, and of the CD56bright cells (approximately 
10% of NK cells), may be NK1 or NK2 depending on the cytokines produced (TH1 
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cytokines or TH2 cytokines, respectively). NK1 cells are CD56
bright and CD16dim, and 
tend to produce higher levels of IFN-γ. NK2 cells are CD56bright and CD16+, tend to 
produce IL-4 and IL-13, and higher numbers of these cells have been observed in 
asthmatic patients. (Wei et al., 2005; Wingett and Nielson, 2003; Scordamaglia et al., 
2008; Deniz et al., 2002). The majority of NK cells, however, (80-90%) are CD56dim and 
CD16+, are more cytotoxic than the CD56bright subset, and are found circulating until 
signaled to migrate toward inflammatory tissue (Bellora et al., 2010; Agaugue et al., 
2008; Timmons and Cieslak, 2008). 
Cytokine Network 
Cytokines, as central components of the immunological signaling network, are 
key mediators of pulmonary allergic responses. Cytokines possess the potential to 
affect specific antigen presenting cell populations (Mannie et al., 2007b; Blanchfield and 
Mannie, 2010), upregulate TRegs, bias the immune system toward TH1, TH2, or TH17 
responses (Kim et al., 1997; Maecker et al., 2001), affect immunological tolerance to 
antigen (Mannie et al., 2007b; Blanchfield and Mannie, 2010), and recruit and activate 
various immune cell types. Cytokines involved in pulmonary allergy pathogenesis 
include general cytokine growth factors and acute response cytokines such as IL-2, a 
growth factor for lymphocytes; granulocyte-macrophage colony-stimulating factor, a 
growth factor for neutrophils, eosinophils, and basophils; and Tumor Necrosis Factor α, 
a key initiator of the allergic acute phase response (Smith, 1988; Ganesh et al., 2009). 
Also involved in pulmonary allergy pathogenesis are the canonical TH2-specific 
cytokines (Interleukin (IL)-4, IL-5, and IL-13); TH1 and innate immunity cytokines (IFN-γ, 
IL-12); TH17, TH22, and lesser known, but prominently expressed cytokines (IL-6, IL-9, 
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TSLP/Ox40L pathway, IL-22, IL-25, IL-33); as well as cytokines involved in the 
immunosuppressive TReg network (IL-10, Osteopontin, TGF-β) (Chung and Barnes, 
1999; Konno et al., 2011; Barnes, 2008). This complex network is responsible for 
driving, in large part, the immune system reaction to antigen in asthma pathogenesis. 
General Growth and Acute Response Cytokines 
IL-2 
IL-2 is a general growth factor for lymphocytes. The primary source of IL-2 is 
activated T cells, and activation of the TCR induces both secretion of IL-2 and 
expression of IL-2R. Activation of the IL-2R induces differentiation and clonal expansion 
of antigen-specific CD4+ and CD8+ T cells, as well as growth and differentiation of B 
cells, NK cells, macrophages, and TReg cells (Chung and Barnes, 1999; Stern and 
Smith, 1986; Beadling and Smith, 2002; Beadling et al., 1993; Letourneau et al., 2009). 
Consistent with its function as a general growth factor, IL-2 has been implicated 
in allergic responses, cytotoxicity, and peripheral tolerance (Smith, 1988; Letourneau et 
al., 2009; Klebb et al., 1996; Fehervari et al., 2006; Thornton et al., 2004; Renauld, 
2001). Lack of IL-2 is associated with lymphoproliferative disorder and autoimmunity 
(Smith, 1988; Thornton et al., 2004; Sakaguchi et al., 1995; Thornton and Shevach, 
1998).  Thus, in the context of allergic disorders, IL-2 appears to play a supportive role 
opposed to a direct pathogenic role. 
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) 
GM-CSF is a general growth factor for neutrophils, eosinophils, basophils, in 
addition to myeloid APCs such as macrophages and dendritic cells (Shin et al., 2009). 
 17 
GM-CSF is primarily produced by T cells, as well as diverse cell types found in the 
airway mucosa including epithelial cells, smooth muscle cells, macrophages, fibroblasts, 
endothelial cells, and eosinophils (Chung and Barnes, 1999). GM-CSF signals through 
the GM-CSF receptor, found in low levels on hematopoietic cells. The GM-CSF receptor 
is comprised of a CD116 α chain and a common β chain, through which other cytokines 
such as IL-3 and IL-5 may interact. The β chain, the primary subunit involved in signal 
transduction, signals through JAK2, in turn activating STAT, MAPK, and P13K pathways 
(Shi et al., 2006; Broughton et al.).  
The importance of GM-CSF in macrophage function is illustrated in GM-CSF 
knockout mice, which develop alveolar proteinosis, a state characterized by impaired 
macrophage function, an accumulation of surfactant in the airways, and inefficient gas 
exchange (Hamilton and Anderson, 2004). Alveolar proteinosis can also develop due to 
defects in the β chain of the GM-CSF receptor, causing interference with GM-CSF 
signaling (Hamilton, 2002). GM-CSF overexpression in human populations, caused by 
certain malignancies such as myeloid leukemia, results in the differentiation of 
cancerous cells as well as the generation of GM-CSF-neutralizing auto-antibody and 
subsequent alveolar proteinosis (Shi et al., 2006; Hamilton, 2002). Neutropenia caused 
by cancer or resulting chemotherapy treatment may be treated with GM-CSF or with 
recombinant GM-CSF therapies such as Sargramostim (Leukine) to mobilize stem cells. 
Bone marrow transplant recipients may also receive GM-CSF therapy to aid in myeloid 
reconstitution. Patients receiving GM-CSF therapy that have also been diagnosed with 
rheumatoid arthritis, however, experience a worsening of arthritis symptoms as a side-
effect, indicating a pro-inflammatory role for GM-CSF (Shi et al., 2006). 
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Further supporting a pro-inflammatory role for GM-CSF, GM-CSF has been 
observed to contribute to TH17-induced inflammatory responses, and transgenics 
expressing GM-CSF in the stomach have been shown to develop autoimmune gastritis 
(Shi et al., 2006; McGeachy, 2011). In studies with GM-CSF knockout mice, mice are 
resistant to development of EAE and type I diabetes in the respective disease models 
(Hamilton, 2002; Enzler et al., 2007). In asthma models, treatment with anti-GM-CSF 
antibody attenuates sensitization to aeroallergens, allergen-induced inflammation, and 
AHR (Hamilton and Anderson, 2004). Consistent with the mucosal sources of GM-CSF, 
GM-CSF mRNA is increased in the airways of human asthmatics (Chung and Barnes, 
1999) where it promotes maturation, activation, and growth of monocytes and DCs 
resulting in increased antigen presentation and activation of antigen-specific B and T 
cells (Blanchfield and Mannie, 2010; Ganesh et al., 2009; Hamilton and Anderson, 
2004; Ritz et al., 2002). Clinical application of GM-CSF inhibition has been seen with 
Mavrilmumab, a rheumatoid arthritis treatment targeting GM-CSFRα, and with MOR 
103, an anti-GMCSF treatment used in multiple sclerosis (Nair et al., 2012; Deiß et al., 
2013). 
GM-CSF has also been shown to exert anti-inflammatory roles, however. GM-
CSF treatment in rodent models of experimental autoimmune myasthenia gravis 
inhibited disease progression through the induction of immunosuppressive TRegs, and 
likewise inhibited experimental autoimmune thyroiditis and type 1 diabetes in rodent 
models through dendritic cell interaction and TReg induction (Cheatem et al., 2009; 
Ganesh et al., 2009; Sheng et al., 2006). Clinical application of GM-CSF has been 
observed with Sipleucel-T (Provenge), an FDA-approved cancer vaccine. In this 
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treatment, a patient’s peripheral blood mononuclear cells (including dendritic cell APC) 
are collected and incubated with GMCSF-PAP, a fusion protein comprised of GM-CSF 
and PAP (prostatic acid phosphatase), a protein found on the majority of prostate 
cancer cells. The cultured cells are then re-introduced into the patient, altering tumor 
antigen presentation and aiding in the tumor immune response (Shore et al., 2013). Due 
to the opposing effects seen for GM-CSF in the rodent type 1 diabetes model, as well 
as opposing pro- and anti-inflammatory effects observed in other models and therapies, 
it is likely that the timing of GM-CSF introduction or the balance of GM-CSF determines 
the nature of its effect.  
Tumor Necrosis Factor-α (TNF-α) 
TNF-α is an initiator of the acute phase response that is produced primarily by 
macrophages, but is also expressed in T lymphocytes, mast cells, neutrophils, 
eosinophils, natural killer cells, and epithelial cells (Costa et al., 1993; Devalia et al., 
1993). TNF-α secretion by monocytes and macrophages is amplified by other cytokines 
such as IL-1, GM-CSF and IFN-α; and IgE has been shown to induce TNF-α expression 
in lung epithelial cells via FcεRI (Ohno et al., 1990; Hirshman et al., 1980; Ohkawara et 
al., 1992). TNF-α receptors, TNF-R55 and TNF-R75, are found on most cells with the 
exception of red blood cells and unactivated T cells. Expression of TNF-R75 is 
particularly high on hematopoietic cells (Chung and Barnes, 1999).  
TNF-α augments allergic reactions by up-regulating MHC-II expression and IL-1 
secretion by APCs (Chung and Barnes, 1999; Kips et al., 1993; Shah et al., 1995) and 
by acting as a costimulatory molecule for activated T cells, allowing for increased T cell 
proliferation and IL-2 receptor expression (Chung and Barnes, 1999). TNF-α induces 
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chemotaxis, degranulation, and respiratory burst activity in neutrophils (Chung and 
Barnes, 1999); and stimulates production of intercellular adhesion molecule (ICAM)-1, 
vascular cell adhesion molecule (VCAM)-1, and E-selectin that mediate migration of 
granulocytes  and mononuclear cells at sites of inflammation (Commins et al., 2010). 
TNF-α expression is elevated in bronchoalveolar lavage fluid (Broide et al., 1992) 
and bronchial biopsies from human asthmatics (Ying et al., 1991), and airway 
responsiveness correlates with TNF-α levels in humans (Berry et al., 2007) and Brown-
Norway rats (Kips et al., 1992). The effects of TNF-α in the airways may be secondary 
to increased production of GM-CSF, IL-8, and RANTES that promote growth and 
recruitment of inflammatory cells (Chung and Barnes, 1999). Inhalation of TNF-α by 
normal human subjects, causes neutrophil-induced AHR (Barnes, 2008). Blockade of 
TNF-α with etanercept (Embrel) and infliximab (Remicade) reduces AHR in patients with 
refractory and moderate asthma, respectively (Barnes, 2008).   
Canonical TH2 Cytokines 
IL-4 
IL-4 was originally described as a B cell growth factor, but is now known to also 
play a critical role in T cell differentiation. IL-4 is produced by TH0 and TH2 T 
lymphocytes, NK T cells, eosinophils, basophils, and mast cells (Commins et al., 2010). 
IL-4 synthesis is enhanced via costimulatory signals generated by cross linking of CD40 
ligand on human CD4+ T cells, activation of TCR, and crosslinking of FcεRI on basophil 
and mast cells (Chung and Barnes, 1999). 
IL-4 promotes differentiation of naive TH0 into TH2 cells, and inhibits apoptotic 
pathways within TH2 cells (Commins et al., 2010). IL-4 is required for immunoglobulin 
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isotype switching to IgE in B cells and stimulates expression of IgE receptors on mast 
cells (Renauld, 2001). IL-4 also promotes antigen presentation by increasing MHC-II 
expression on APCs and increasing expression of B7 (CD80/CD86), CD40, low-affinity 
IgE receptor (CD23), and surface IgM on B cells. Transgenic mice overexpressing IL-4 
develop symptoms of allergic disease including lymphocytic and eosinophilic 
inflammation and elevated IgE concentrations (Renauld, 2001). In humans, the severity 
of asthma has been associated with a gain of function mutation in the IL-4 receptor 
protein (IL-4Rα) (Hershey et al., 1997). Conversely, knock-out of the IL-4 gene in mice 
attenuates ovalbumin-induced eosinophilia and production of allergen-specific IgE, but 
has little effect on AHR (Chung and Barnes, 1999; Renauld, 2001).  Yet, studies utilizing 
anti-IL-4 receptor (IL-4R) antibodies or mice deficient in the IL-4R subunit IL-4Rα 
revealed reductions in AHR. A potential explanation for this discrepancy is that IL-4Rα 
can also bind IL-13, providing a parallel pathway for activation of IL-4Rα and induction 
of AHR (Renauld, 2001).  The overlap in IL-4 and IL-13 signaling through IL-4Rα has 
clinical significance, resulting in reduced effectiveness of therapies targeting IL-4 or IL-
13 alone compared to therapies targeting IL-4Ra (Corren et al., 2010; Slager et al., 
2012). 
IL-5 
IL-5 is a primary growth factor for eosinophils and is produced by TH2 T 
lymphocytes, eosinophils, and mast cells. As the major cytokine in eosinophil 
development, IL-5 induces eosinophil migration, activation, and survival (Chung and 
Barnes, 1999). The primary source of IL-5 is TH2 lymphocytes, but mast cells are also a 
source in the airways. IL-5 is increased in bronchial biopsies and BAL fluid and serum 
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from symptomatic asthmatic patients, knock-out of IL-5 in mice eliminates AHR and 
eosinophilia, and overexpression or treatment with rIL-5 results in asthma-like lung 
histopathology (Chung and Barnes, 1999; Barnes, 2008; Commins et al., 2010). 
Blockade of IL-5 in humans with Mepolizumab, an anti-IL-5 antibody, decreases 
eosinophils in the sputum and general circulation, and in asthma patients exhibiting 
hypereosinophilia and resistance to steroid therapy, Mepolizumab reduces 
exacerbations (Busse et al., 2010). 
IL-9 
IL-9 is secreted by CD4+ cells, typically TH2 cells. Originally described as a T cell 
growth factor, IL-9 induces not only T cell proliferation, but also proliferation and 
differentiation of mast cells and hematopoietic progenitor cells, as well as B cell 
immunoglobulin synthesis. IL-9 has been shown to increase mast cell IgE receptor 
expression, upregulate IgE production, and promote eosinophil growth (Commins et al., 
2010). In mice, mast cell proliferation and stimulation of B cell immunoglobulin synthesis 
appear to be mediated by IL-9 directly, whereas IL-9 effects on eosinophilia and mucus 
production are through IL-13 (Barnes, 2008). 
Both IL-9 and the IL-9R are increased in the airways of asthmatic patients, and the 
expression IL-9 mRNA is correlated with increased airway responses to methacholine 
(Renauld, 2001). Transgenic mice with increased lung expression of IL-9 exhibit 
increased numbers of eosinophils and mast cells in the airways, excess mucus, airway 
remodeling, AHR, and elevated IgE. Conversely, antagonism of IL-9 suppresses 
allergen-induced airway eosinophilia, mucus production, and AHR (Chung and Barnes, 
1999; Barnes, 2008). The ability of IL-9 overexpression to elicit symptoms of airway 
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disease may be due to IL-9-induced upregulation of IL-5 and IL-13 secretion (Finkelman 
et al., 2010). Clinical trials with a therapeutic antibody against IL-9, MEDI-528, have 
shown modest efficacy in asthma (Antoniu, 2010a; Parker et al., 2011). 
IL-13 
IL-13 is produced by activated CD8+ T cells as well as CD4+ TH1, TH2, and TH0 
cells in response to antigenic stimuli (Chung and Barnes, 1999). The IL-13 receptor 
shares a common subunit with the IL-4 receptor, IL-4Rα, and the two cytokines exhibit 
some functional overlap. The other component of the heterodimeric IL-13 receptor 
complex, IL-13Rα, is prominently expressed on smooth muscle cells. Unlike IL-4, IL-13 
has no effect on T cell activation due to a lack of IL-13 receptors on T cells, although 
both IL-13 and IL-4 have been shown to increase IgE secretion and promote remodeling 
of the airway wall. IL-13 increases mucus secretion and airway hyperresponsiveness 
through STAT6 activation in the airway epithelium, and affects eosinophil activation and 
survival through CD69 (Chung and Barnes, 1999; Barnes, 2008).  
IL-13 is elevated in the airways of human asthmatics and correlates with the 
severity of allergen-induced eosinophilia.  In mice, IL-13 causes airway eosinophilia and 
AHR, and neutralization attenuates mucus production, airway eosinophilia, and AHR 
(Chung and Barnes, 1999; Barnes, 2008). Pitrakinra, an IL-4 mutein that blocks binding 
of both IL-13 and IL-4 to IL-4Rα decreases late response to inhaled allergen in humans 
(Antoniu, 2010b), and efficacy is increased in asthmatics with specific polymorphisms 
IL-4Rα (Slager et al., 2012).   
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TH1 Cytokines 
Interferon-γ (IFN-γ) 
 IFN-γ inhibits TH2 cell responses, allergic inflammation, and IgE production; and 
promotes cell-mediated cytotoxicity. IFN-γ production is limited to CD4+ and CD8+ T 
lymphocytes and NK cells, but its receptors are found on diverse cell types including T 
and B cells, DCs, granulocytes, monocytes and macrophages, epithelial and endothelial 
cells, and platelets (Chung and Barnes, 1999). IFN-γ is a potent inhibitor of IL-4-induced 
IgE production by B cells and IL-10 synthesis by monocytes, which results in increased 
production of TNF-α IL-1, platelet activating factor (PAF), and production of ROI.  IFN-γ 
also augments TNF-α effects on airway smooth muscle cells, upregulating RANTES 
synthesis. 
The role of IFN-γ is asthma is not clearly understood.  Consistent with its role as 
an inhibitor of TH2 responses, production of IFN-γ is reported to be low in mild 
asthmatics (Truyen et al., 2006).  Similarly, inhaled recombinant IFN-γ decreases the 
number of eosinophils in BAL fluid from asthmatic patients.  In mice exposed to 
allergen, treatment with IFN-γ attenuates eosinophil infiltration in the airways and AHR, 
and knock-out of the IFN-γ receptor increases airway eosinophil infiltration (Chung and 
Barnes, 1999).  However, IFN-γ is not entirely protective and has been shown to 
stimulate the expression of cysteinyl leukotriene receptor CysLTR-2 on eosinophils, 
which can contribute to cysteinyl leukotriene-mediated bronchoconstrictive and 
inflammation (Fujii et al., 2005). In addition, sputum IFN-γ levels are reported to be 
higher in severe asthma than in mild asthma (Truyen et al., 2006).   
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IL-12 
IL-12 is primarily produced by monocytes and macrophages, and to a lesser 
degree by B cells and dendritic cells. IL-12 receptors are located mainly on T cells and 
NK cells, and stimulate TH1 and NK cell growth, while inhibiting TH2 cell responses. IL-
12 augments cytotoxicity by T lymphocytes and NK cells, at least in part through the 
enhancement of IFN-γ and TNF-α secretion, and inhibition of IL-4 production. 
Consequently, IL-12 favors TH1-type responses over TH2-type and IgE inflammation, 
and may serve as a regulator of IgE-related inflammation in pulmonary allergic disease 
(Chung and Barnes, 1999).  
In patients with allergic asthma, levels of IL-12 in whole blood are reduced, and 
IL-12 stimulated IFN-γ production is less than in healthy controls.  IL-12 mRNA is 
reduced in airway biopsies from allergic asthma patients, and the levels are increased 
by administration of corticosteroids. In mice, IL-12 treatment reduces eosinophilia, IgE 
release, and AHR, but only if administered during active sensitization.  IL-12 
administered post-sensitization shows little or no difference from controls (Chung and 
Barnes, 1999). Thus, the effects of IL-12 are dependent upon the state of the allergic 
response.   
Noncanonical Cytokines 
IL-6 
Originally described as a B cell growth factor, IL-6 is now recognized as a 
pleiotropic cytokine synthesized by diverse cell types, including T and B cells, 
monocytes and macrophages, bone marrow stromal cells, keratinocytes, fibroblasts, 
eosinophils, endothelial cells, and epithelial cells. Production of IL-6 is augmented by IL-
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1, TNF-α, platelet-derived growth factor, and LPS. IL-6 signals through a receptor 
complex comprised of gp130 and IL-6R, which is found primarily on leukocytes and 
hepatocytes (Dienz and Rincon, 2009).  
IL-6 plays a role in the differentiation, growth, and activation of T and B 
lymphocytes, and stimulates production of IgG, IgA, and IgM (Akdis et al., 2011). IL-6 is 
crucial to IL-4-induced IgE production, enhances IL-2 production and CD4 T cell 
survival, and promotes TH2 cell differentiation (Chung and Barnes, 1999; Akdis et al., 
2011). In addition, IL-6 can potentially exert anti-inflammatory activity through the 
inhibition of IL-1 and TNF synthesis by macrophages (Chung and Barnes, 1999).  
In asthmatic patients, IL-6 secretion is elevated both at rest and after allergen 
challenge. In vitro, monocytes and macrophages release IL-6 in response to IgE. In 
transgenic mice expressing IL-6, mice show decreased AHR and increased numbers of 
airway lymphocytes (Chung and Barnes, 1999). A therapeutic antibody against IL-6, 
siltuximab, is in clinical trials for cancer, but its application to asthma has not yet been 
reported (Hudes et al., 2012).  
Thymic Stromal Lymphopoietin (TSLP) 
TSLP is a key initiator of allergic inflammation and considered to be one of the two 
major cytokines involved in mucosal TH2 immune deviation along with IL-33. The 
cytokine is increased in asthmatic airways and mast cells (Barnes, 2008; Bird, 2005), 
and in the lungs is produced mainly by airway epithelial cells.  Inflammation in allergic 
lung disease may be exacerbated by the ability of TSLP to react synergistically with IL-
10 and TNF-α to stimulate mast cell growth and release of TH2 cytokines. TSLP may 
also positively influence TH2 cytokine release from CD4+ T cells. In addition, TSLP 
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stimulates the production of TH2 chemoattractants CCL17 and CCL22 from airway DCs, 
leading to TH2 airway infiltration (Barnes, 2008).  
In TSLP receptor deficient mice, TH2 cells, CCL11, and CCL17 in BAL were 
decreased and airway inflammation was reduced compared to wild-type mice. Adoptive 
transfer of wild-type CD4+ cells with normal TSLP receptors into the receptor deficient 
mice restored airway inflammation, indicating the TSLP was involved in T cell activation 
(Bird, 2005). Overexpression of the Tslp transgene in lung epithelial cells results in 
airway infiltration by eosinophils and TH2 cells, and development of AHR. Blocking 
OX40 ligand (OX40L), an important mediator of TSLP signaling, inhibits allergic 
inflammation in mice and non-human primates (Barnes, 2008). The findings with TSLP 
and OX40 ligand have not yet been translated into human therapy for asthma. 
IL-22 
In humans, IL-22 is primarily produced by TH1 and TH22 helper T cells, but can 
also be produced by TH17 cells, mast cells, and NK cells.  In mice, however, IL-22 is 
predominately produced by TH17 cells. IL-22 receptors are heterodimers composed of 
IL-22R1/IL-10R2 chains. IL22R1 is not expressed on immune cells, and the major role 
appears to be stimulation of hepatocyte production of acute phase proteins and 
stimulation of non-hematopoietic cell genes implicated in innate immunity, inflammation, 
chemotaxis, and cell proliferation (Sonnenberg et al., 2011). 
IL-22 can exhibit proinflammatory or anti-inflammatory activity depending on the 
tissue and the cytokine milieu (Besnard et al., 2011). In a study by Besnard et al., 
investigators noted increased IL-22 protein concentrations in serum from asthmatic 
patients, and increased IL22 transcript and IL-22 protein in the lungs in an ovalbumin-
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induced murine model of asthma. Within the murine asthma model, it was found that IL-
22-KO mice exhibited significantly less airway inflammation accompanied by decreased 
IL-4, IL-13, IL-33, CCL11, and CCL17, as well as increased IL-17A compared to normal 
WT controls. Similarly, normal WT controls exhibited less inflammation if treated with an 
IL-22-neutralizing antibody during the sensitization phase, suggesting that IL-22 plays a 
pro-inflammatory role in the induction of airway inflammation. Once inflammation was 
established, however, administration of IL-22-neutralizing antibody amplified IL-17A and 
TH2 cytokine production, and cellular infiltration, while administration of exogenous IL-22 
during this phase reduced IL-17A and intracellular infiltration. This suggests a 
protective, anti-inflammatory activity for IL-22 in established inflammation. In addition, 
there were indications of a reciprocal regulation between IL-22 and IL-17A, with IL-22 
being required for IL-17A-induced inflammation (Besnard et al., 2011). 
IL-25 
IL-25, or IL-17E, is produced by TH2 cells, epithelial cells, activated mast cells, 
alveolar macrophages, activated eosinophils and basophils (Barnes, 2008; Pappu et al., 
2008). The receptor for IL-25 is IL-17BR (also known as EVI27), and activation results 
in airway inflammation mediated via CD4+ T cells and the STAT6 pathway. In vitro, IL-
25 enhances the release of TH2 cytokines from TH2 cells both during and after 
differentiation. In mice, IL-25 increases expression of IL-4, -5, and -13; leading to 
eosinophilic inflammation, elevation of IgE, mucus and epithelial cell hyperplasia, and 
AHR. Overexpression in the lung induces allergic TH2 responses characterized by 
increased numbers of macrophages and eosinophils, and mucus secretion. In contrast, 
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IL-25 blockade attenuates allergen-induced AHR, lung eosinophilia, and antigen-
specific TH2 cells (Pappu et al., 2008). 
In asthma patients, eosinophils and basophils are described as the major source 
of IL-25. IL-25 RNA is elevated in the lungs of chronic asthmatics, and IL-25 positive 
cells in the bronchial submucosa of these patients are reported to have eosinophil-like 
characteristics (Monteleone et al., 2010). IL-25 and TSLP stimulate human TH2 memory 
cells in the presence of DCs to produce IL-4, IL-5, and IL-13 (Pappu et al., 2008). In 
addition to enhancing TH2-related responses, IL-25 limits TH1- and TH17-related 
inflammatory responses associated with diseases such as Multiple Sclerosis, diabetes, 
and inflammatory bowel disease. Thus, while anti-IL-25 therapies have the potential to 
alleviate asthma and allergic inflammation, the approach might increase the risk for 
autoimmune-related activity (Monteleone et al., 2010). 
IL-33 
IL-33 is considered to be one of major cytokines involved in TH2 immune deviation. 
It is produced primarily by bronchial epithelial cells, but can also be produced by smooth 
muscle cells, macrophages, DCs, and fibroblasts (Barnes, 2008; Commins et al., 2010).  
ST2, the IL-33 receptor, is located on TH2 cells, mast cells, basophils, eosinophils, NK 
cells, and NKT cells.  ST2 acts through an IL-1 receptor-related signaling cascade. The 
soluble form of the receptor, sST2, is produced in response to anti-inflammatory signals 
and acts to bind and reduce IL-33 activity. IL-33 is released during inflammation and 
tissue damage, and is therefore classified as an “alarmin” (Smith, 2010).   
IL-33 exerts both nuclear and extracellular effects. IL-33 aids in TH2 cell 
differentiation by translocating to the nucleus, and altering chromatin structure and 
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transcription. Extracellular effects of IL-33 include its role as a TH2 activator and 
chemoattractant, and as a promoter of TH2 cell production of IL-5 and IL-13. IL-33 is not 
limited to enhancement of TH2 cytokine production from TH2 cells, but can also induce 
IFN-γ production from TH2 cells. The ability of IL-33 to enhance production of both IL-13 
and IFN-γ provides a potential explanation for why some chronic asthma patients exhibit 
mixed TH1/TH2 cytokine profiles. 
In addition to exerting effects on TH2 T cell function, IL-33 aids in promoting 
eosinophil survival and adhesion to proteins in the extracellular matrix. IL-33 has also 
been shown to enhance mast cell survival and activation, as well as mast cell 
production of IL-6 and IL-13. These effects are further enhanced when IL-33 is 
accompanied by TSLP or IgE crosslinking (Smith, 2010). 
In human asthmatics, there is a significant elevation in the concentration of sST2, 
possibly as a compensatory response to elevated IL-33 levels (Smith, 2010). In mice, 
treatment with IL-33 receptor antagonists downregulates TH2 cytokines and allergen-
induced inflammation, while treatment with IL-33 produces a TH2 deviation, an 
escalation in TH2 cytokines and IgE, and lung eosinophilia (Commins et al., 2010). 
Elucidation of IL-33’s role in pulmonary allergic responses is an active area of research 
at this time. 
TReg Cytokines 
 IL-10 
IL-10, originally described as “cytokine synthesis inhibitor factor”, is produced by 
TH0, TH1, TH2, TReg, cytotoxic T cells, mast cells, and activated monocytes. IL-10 
receptors are located on lymphoid, myeloid, and NK cells. IL-10 decreases TH2 
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signaling by downregulating MHC-II, B7.1/B7.2 and CD23 expression (Chung and 
Barnes, 1999). IL-10 suppresses monocyte and macrophage activity, including release 
of ROI, and downregulates secretion of pro-inflammatory cytokines such as IL-1β, TNF-
α, IL-6, IL-8, and MIP-1α. In TH1 cells, IFN-γ and IL-2 synthesis are inhibited, as is 
synthesis of IL-4 and IL-5 by TH2 cells. In contrast, IL-10 can promote growth of mast 
cells, T cells, and B cells. However, even these responses can be bimodal, with 
inhibition observed at high concentrations of IL-10. 
IL-10 mRNA and protein are reduced in alveolar macrophages from asthmatic 
patients, but the number of IL-10 expressing T cells and macrophages may be 
increased. In Brown Norway rats, IL-10 is reported to attenuate late-phase responses 
and eosinophilia post-challenge. In mice, treatment with IL-10 at the time of 
sensitization decreases eosinophilia (Barnes, 2008). Studies involving antibodies 
against IL-10 and IL-10R, as well as IL-10 knockout have revealed attenuation of AHR 
and eosinophilia. This apparent inconsistency in the typical TH1 functioning of IL-10 
might be explained by the finding that IL-10 can inhibit IL-13Rα2, a protein responsible 
for binding and inhibiting IL-13, thereby potentially increasing IL-13 effects. It has been 
noted that mice lacking both IL-10 and IL-13Rα2 exhibit a more severe manifestation of 
pulmonary allergic disease than mice deficient in IL-10 or IL-13Rα2 alone (Finkelman et 
al., 2010). 
Osteopontin (OPN) 
Osteopontin is a TH1 cytokine implicated as a potential regulator of allergic 
responses. OPN is produced by monocytes and monocyte-derived DCs and acts as a 
chemoattractant for monocytes, neutrophils, and lymphocytes (Konno et al., 2011). In 
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vivo studies with asthmatic patients have shown a significant correlation between OPN 
expression and eosinophilia in bronchoalveolar lavage fluid. OPN may also contribute to 
airway remodeling through the regulation of cellular interactions with extracellular matrix 
as well as the expression of matrix metalloproteinase (MMP). In mice, OPN is positively 
correlated with airway remodeling and stimulates collagen deposition in cell cultures. In 
addition, ovalbumin sensitization and challenge of Osteopontin-deficient mice results in 
an accentuated allergen-specific-IgE response. It has also been observed, however, 
that treatment with an anti-OPN antibody downregulates Ag-specific IgE and 
upregulates pDCs (Xanthou et al., 2007). This discrepancy in observations may have 
been due to the use of antibodies that recognized different domains on OPN, as it has 
been shown that the function of OPN can be dependent upon the ligated domain 
(Konno et al., 2011). In studies by Koguchi et al., the effects of OPN on IL-12 and IFN-γ 
production by PBMCs could be attenuated with a C-terminal-specific anti-OPN Ab, 
though not with an integrin-binding-domain anti-OPN Ab (Koguchi et al., 2003). It would 
seem, then, that effects exerted by OPN may change depending on the functional 
domain involved in the response. While OPN may play a role in the allergic response 
pathway, more studies are needed to elucidate the diverse nature of these roles. 
Transforming Growth Factor-β (TGF-β) 
TGF-β is a pro-fibrotic growth factor produced by activated monocytes, pulmonary 
macrophages, eosinophils, neutrophils, airway epithelial cells, smooth muscle cells, 
mast cells, lung fibroblasts, T helper and TReg lymphocytes (Chung and Barnes, 1999; 
Commins et al., 2010). In chronic allergic inflammation, eosinophils are a primary 
source of TGF-β (Commins et al., 2010; Akdis and Akdis, 2009). TGF-β receptors 
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include high-affinity (type I and type II) and low-affinity (type III) isoforms (Chung and 
Barnes, 1999). TGF-β is a strong stimulating factor for epithelial cell differentiation and 
fibroblast secretion of extracellular matrix proteins, contributing to the airway remodeling 
observed in chronic pulmonary allergic disease pathology. In addition, TGF-β is also a 
powerful chemoattractant for monocytes, mast cells, and fibroblasts.  
TGF-β has contrasting roles in allergic disease pathology. Depending on the 
cytokine milieu, it can either stimulate or inhibit proliferation of airway smooth muscle 
cells and fibroblasts (Chung and Barnes, 1999; Commins et al., 2010). Likewise, TGF-β 
can be pro-inflammatory by augmenting differentiation of TH17 and TH9/IL-9-producing-
TH2 cells, or anti-inflammatory by inhibiting IgE production, mast cell proliferation, T cell, 
B cell, NK cell, and cytotoxic lymphocyte functions (Akdis and Akdis, 2009). One of the 
factors affecting the role played by TGF-β is peptidyl-prolyl isomerase Pin1 (protein 
NIMA-interacting 1). Pin1, shown to regulate eosinophil GM-CSF production, has also 
been shown to regulate eosinophil TGF-β production. Compared with normal control 
animals, inhibition of Pin1 in rat models of allergic disease caused decreased 
expression of TGF-β1 and type I collagen, decreased eosinophilia in bronchoalveolar 
lavage fluid, and a decline in fibrotic deposits in the lungs (Shen et al., 2008). In human 
asthma patients, increases in TGF-β have been observed in bronchoalveolar lavage 
fluid following allergen challenge, and TGF-β expression seems to have a positive 
correlation with increased basement membrane thickness, subepithelial fibrosis, and 
severity of asthma symptoms (Renauld, 2001). 
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Models of Allergic Asthma  
 Respiratory allergies and asthma are considered human diseases and with few 
exceptions, are not naturally-occurring in laboratory animals. Allergic reactions to 
aeroallergens in humans develop over the lifetime and change with environmental 
factors; and no animal model fully recapitulates the chronic human disease. Even so, 
animal models have proved useful in investigating the pathways underlying pulmonary 
allergic responses, developing mechanistic hypotheses to explain pathogenesis, and 
testing novel therapeutics. Models of allergic asthma have been implemented in mice, 
rats, guinea pigs, rabbits, dogs, sheep, horses, and non-human primates; each with 
distinct advantages and disadvantages. 
Mice 
The murine model of asthma has been the most widely-used in recent years due 
to the amount known about murine immunology, high availability of commercial species-
specific reagents, ease of genetic manipulation leading to wide-availability of transgenic 
and knock-out strains, low cost of husbandry, and relative low level of social sensitivity 
and federal regulatory oversight. Mice can be sensitized to a wide array of allergens 
such as ovalbumin (OVA), and house dust mite (HDM), Aspergillus fumigatus, ragweed, 
and cockroach antigens (Zosky and Sly, 2007). Mouse models incorporating AHR, 
bronchopulmonary inflammation, and increases in IgE and mucus production have been 
described, and some chronic models have shown airway remodeling - all key features 
of human asthma. Inflammation and AHR vary across murine models of asthma, due in 
some part to strain-dependent differences in airway smooth muscle and predisposition 
to TH1 and TH2 mediated inflammation (Safholm et al., 2011). 
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Disadvantages of the mouse model include distinct anatomical and 
immunological differences between mice and humans (Wenzel and Holgate, 2006). 
Mouse lungs have fewer airway generations, and most airways lack the smooth muscle 
bundles found in human airways, which may contribute to differences in 
bronchoconstriction and AHR. Second, mice can be manipulated to accentuate TH1 or 
TH2 phenotypes, murine models of asthma are predominately TH2 in nature. But there is 
a greater amount of overlap of these pathways in humans, and some human asthmatics 
have been observed to have increased levels of IL-12 and IFN-γ suggesting increased 
TH1 involvement in these subjects (Wenzel and Holgate, 2006). Thirdly, while AHR has 
been observed in murine models of asthma, it is not clear whether or not mouse models 
reliably demonstrate late-phase responses as would be observed in humans (Safholm 
et al., 2011). In addition, many murine models of asthma lack chronicity in post-
sensitization allergen responses. Following repeated allergen challenge, tolerance to 
allergen and diminished immune responses have been observed in many of these 
models. Careful titration of allergen exposure is required to induce long-term 
hyperresponsiveness, airway remodeling, and eosinophilia in the mouse (Kumar and 
Foster, 2002).   
Immunological pathways shown to be important in mouse models have not easily 
translated to new treatments for human disease. Early clinical trials with anti-IL-4 and 
anti-IL-5 antibodies yielded disappointing results, and lack of efficacy in preventing 
asthma symptoms is often cited as lack of fidelity between mouse models and human 
asthma (Wenzel and Holgate, 2006). However, more recent studies with altered 
experimental design, modified exclusion criteria, use of biomarkers to identify 
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responsive asthmatic subjects, refinement of pharmacodynamic measures, and 
optimization of dosing has yielded encouraging results. For example, Pitrakinra exhibits 
greater efficacy in asthmatics with specific single nucleotide polymorphisms in IL-4Rα, 
(Slager et al., 2012), and Mepolizumab is somewhat more effective in steroid-refractory 
patients with hypereosinophilia than in the general population of mild and moderate 
asthmatics (Nair et al., 2009; Haldar et al., 2009). This controversy aside, the mouse 
remains an important tool for elucidating pathways involved in immune responses and 
identifying potential novel targets, and is often used in research due to the availability of 
a multitude of commercial species-specific reagents and wide-availability of inbred, 
transgenic, and knock-out strains. 
Rats 
 Rats are small and inexpensive, but large enough to obtain ample serum and 
bronchoalveolar lavage fluid for analysis. In addition, they are large enough to be stable 
under anesthesia, which facilitates measurements of pulmonary resistance, compliance, 
and AHR (Zosky and Sly, 2007). Rats can be sensitized to a wide array of allergens 
including OVA, HDM, and Ascaris antigens resulting in a TH2 eosinophilic inflammation 
and IgE responses, although the strength of the responses can be strain-specific. 
Compared with mice, however, rats have fewer transgenic and knock-out strains as well 
as a lack of species-specific reagents, ultimately limiting their usefulness in asthma 
research. 
Guinea Pigs 
 Guinea pigs, utilized in some of the earliest models of allergic airway responses, 
present early and late phase responses with concurrent AHR and eosinophilia, much 
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like human manifestations of the disease. Following sensitization, the response of 
guinea pigs to methacholine, histamine, and allergen are similar to responses observed 
in human airways, but serotonin also induces marked bronchoconstriction in guinea pigs 
that is not seen in humans. In addition, differences are observed in response to 
leukotrienes, indicating an underlying mechanistic distinction between humans and 
guinea pigs. Guinea pigs also have elevated numbers of eosinophils prior to 
sensitization and challenge, and in chemical irritant studies, the immunological 
response of guinea pigs is often acute and sometimes fatal, requiring pre-treatment with 
antihistamines to dampen the severity of the immune response. As with rats, however, 
few inbred strains and species-specific reagents are available (Shin et al., 2009). 
Rabbits 
 Rabbit asthma models exhibit early and late phase responses, and as with 
humans, the rabbit lung is the primary site of IgE-mediated anaphylactic responses 
(Shin et al., 2009; Zosky and Sly, 2007; Karol, 1994). An early phase response to 
allergen characterized by increased lung resistance and decreased dynamic 
compliance is observed within 15 minutes of challenge in this model, followed by a late 
phase response starting within 2 hours. In this model, neonatal immunization is needed 
to facilitate development of the late phase response. 
Dogs 
 Dogs, unlike rodents and rabbits, may become naturally sensitized to antigens 
that also affect the human population (Zosky and Sly, 2007). Such naturally-occurring 
allergic reactions in dogs do not typically induce asthma-like symptoms despite an 
elevation in airway eosinophilia, however. Instead, the responses present as dermatitis 
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or conjunctivitis (Zosky and Sly, 2007). In contrast to the lack of an airway response in 
naturally occurring allergic reactions, there are canine models of asthma that show 
airway constriction and AHR in addition to increased IgE and eosinophilia. The Basenji 
Greyhound model, for example, shows AHR as well as responsiveness to 
methacholine, though baseline AHR is elevated in this model and AHR does not always 
mark clinical disease (Karol, 1994). Although canine models have the potential for 
evaluating chronic responses to allergen, they are relatively expensive, require 
additional time for breeding and sensitization, and, as with other larger-animal models, 
there are fewer species-specific reagents. 
Sheep 
 Sheep present early and late phase responses that involve AHR and eosinophilia 
(Karol, 1994). As seen with some dogs, sheep can become naturally sensitized to 
Ascaris suum, though these responses vary from animal to animal (Zosky and Sly, 
2007). Some sheep respond with an early phase response only, while 30-50% respond 
with both early and late phase responses, mimicking the variability found in the human 
population. AHR is observed in sheep exhibiting a late phase response, within 24 hours 
post-challenge. The allergic response in sheep and the timing of mediators observed 
during allergic pathogenesis, particularly LTE4, shares many similarities with human 
asthma patients (Zosky and Sly, 2007). As in humans, cromolyn and corticosteroids are 
effective in sheep. Dissimilar to humans, however, is that allergic responses in sheep 
lungs may be ameliorated through the use of drugs targeting platelet activating factors 
(Zosky and Sly, 2007). Despite some similarities to aspects of human asthma 
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pathogenesis, sheep, like dogs, are larger and much more costly to maintain than 
smaller species, and fewer species-specific reagents are available.  
Horses 
 Horses, naturally sensitized to a “barn environment,” develop AHR and recurrent 
episodes of disease (Shin et al., 2009). Following exposure to hay or barn dust, horses 
show elevated breathing rates and decreased tidal volume during an acute response 
(Karol, 1994). Increased lung resistance and decreased dynamic compliance have also 
been observed. In addition, sensitized horses show serum antibodies to allergen, goblet 
cell metaplasia, increases in airway smooth muscle, and inflammatory cell infiltration. 
Despite the similarities to aspects of human asthma pathogenesis especially the 
spontaneous recurrence of disease, horses, as with other larger animal species, are far 
more costly and fewer species-specific reagents are available.  
Non-Human Primates 
 Non-human primates (NHPs) arguably share the most similarity with humans and 
have been used in asthma studies for over 40 years. While some NHPs are naturally 
sensitive to Ascaris antigen, most protocols involve active sensitization with antigens 
implicated in human asthma (Karol, 1994; Coffman and Hessel, 2005). Humans and 
NHPs share many genetic, immunological, and physiological similarities, and human 
reagents can often be used in NHPs (Coffman and Hessel, 2005). NHP and human 
lungs are similar in size, anatomy, and ultrastructure; and pulmonary function 
measurements that can be made, the instruments that are used, and the techniques are 
similar as well. Many of the characteristics central to human asthma have been reported 
in monkeys, including allergen-specific IgE cutaneous and airway responses, elevated 
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TH2 cells in the airways, eosinophilia, goblet cell hyperplasia, airway remodeling, and 
histamine and methacholine sensitivity (Hyde et al., 2006). Only cynomolgus macaques 
and baboons could generate responses to leukotrienes, however, perhaps indicating a 
closer connection between airway response mechanisms for human subjects and these 
two species than other NHP species.  While NHPs offer many advantages in modeling 
human pathophysiology, in addition to cost and social sensitivities, their social 
environment is complex, and responses to social stress can be very different from 
humans, which can affect their responses to corticosteroids.  
Available Therapeutics  
 Extensive progress has been made in defining the immunological processes 
involved in allergic lung diseases, many owing to basic science experimentation with 
various animal models, but further complexities in development and regulation of 
immune processes, as well as complexities in the interaction of the immune system with 
cellular and molecular pathways controlling development and function of the pulmonary 
system, have thwarted development of novel efficacious therapeutics. Two factors that 
could enhance drug development in this area are: 1) emerging appreciation for distinct 
genotypes and phenotypes in asthma, and 2) elucidation of innate immune pathways 
that parallel, duplicate, enhance, and oppose adaptive immune pathways.  
 To date, the management of asthma symptoms has largely been through the use 
of bronchodilators, inhaled steroids, and corticosteroids. Leukotriene inhibitors and anti-
IgE therapies have also been prescribed. Bronchodilators may be short- or long-acting, 
and generally contain one or a mixture of β2 adrenergic agonists (short- or long-acting), 
anti-cholinergics (paired with short- or long-acting agents), and/or theophylline (long-
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acting) (Spencer and Krieger, 2013). Short-acting bronchodilators can be used to 
reverse symptoms once they have appeared or as an emergency measure, but do not 
manage the underlying inflammation. Long-acting bronchodilators do not provide the 
relief of short-acting bronchodilators, but are typically used together with inhaled 
steroids for added prevention of acute attacks. Inhaled steroids and corticosteroids are 
used to lessen airway inflammation in an effort to reduce the chances of the onset of an 
acute asthma attack. They must be taken 1-2 times daily or as prescribed to help 
control inflammation, but are not useful once symptoms are present. Leukotriene 
inhibitors have been used due to their anti-inflammatory effects, but are not as effective 
as corticosteroids and are therefore used for mild or moderate asthma cases or in 
conjunction with corticosteroids (Spencer and Krieger, 2013). 
 Specific Immunotherapy (SIT) has also been used in an attempt to reduce 
symptoms through building tolerance. With this form of therapy, very small amounts of 
the antigen are injected subcutaneously in an effort to build tolerance to the antigen due 
to re-exposure over time. At the start, patients receive small doses once or twice a week 
over a period of several months, then the dose is increased and given every two to four 
weeks for approximately four or five months, and finally, doses are given around once a 
month for a period of years. Due to the rare chance that anaphylactic shock may occur 
after injection with the allergen, therapy is performed under careful observation. 
Noteworthy is that most of the serious adverse reactions and fatalities have been due to 
SIT for asthma rather than for other conditions such as allergic rhinitis and venom 
hypersensitivity, suggesting that SIT should not be used for patients with severe asthma 
(Frew, 2010). While immunotherapy may be a worthwhile investment for some, it is 
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costly with regard to both time and monetary expense, and may or may not be 
efficacious, depending on the individual and sensitivity to the allergen.  
Definition of phenotype-specific pathogenic factors has shown some promise in 
establishing effectiveness of agents targeting the IL-4 and IL-13 pathways. Elucidation 
of the role of innate immunity in asthma is leading to better understanding of how lipids 
and viruses can induce exacerbations in allergic asthmatics, even when their allergies 
are otherwise well controlled. However, other than some encouraging results from 
animal studies with agents that interrupt inflammation induced via the OX40 pathway 
(Kaur and Brightling, 2012), and modest effects of Pitrakinra (recombinant protein 
targeting IL-4Rα, attenuating IL-4 and IL-13 signaling) (Antoniu, 2010b), MEDI-528 
(anti-IL-9 antibody) (Antoniu, 2010a; Parker et al., 2011), Mepolizumab (anti-IL-5 
antibody), and Omalizumab (anti-IgE Fc domain antibody) (Busse et al., 2010; Nair et 
al., 2009; Haldar et al., 2009; Wenzel, 2009; Belliveau, 2005), little has emerged in 
terms of translating the basic observations into effective and affordable treatments. It is 
important, therefore, to continue investigations into new, novel therapeutics. 
Tolerogenic Therapeutic Vaccines 
 Cytokines, as a central component of the immunological signaling network, have 
long been investigated as potential therapeutics for asthma. While methods for simply 
enhancing or inhibiting the biological activity of specific cytokines have not yet yielded a 
suitable treatment (Simon, 2006), the fusion of cytokines to immunogen has shown 
promise in applied animal models for asthma as well as other immune-mediated 
disease models such as experimental autoimmune encephalitis (EAE) (Mannie et al., 
2007b; Kim et al., 1997; Maecker et al., 2001). In this system, the fusion of cytokine 
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DNA to immunogen DNA yields a single polypeptide following translation that retains 
the functionality of each original domain. These cytokine fusion proteins have 
demonstrated the ability to bias the immune system toward Th1 responses (Kim et al., 
1997; Maecker et al., 2001), target antigen to specific antigen presenting cell 
populations, as well as induce immunological tolerance to antigen (Mannie et al., 2007b; 
Blanchfield and Mannie, 2010). Fusion proteins incorporating GM-CSF, in particular, 
have demonstrated potential to target antigen to APC and induce immunological 
tolerance (Mannie et al., 2007b; Blanchfield and Mannie, 2010). 
Goal of Research and Statement of Hypothesis 
Recent studies have indicated that targeting immunogens to specific immune 
cells via fusion with cytokines increases the effectiveness of immunotherapy in animal 
models for asthma as well as other immune-mediated disease models such as 
experimental autoimmune encephalitis (Mannie et al., 2007b; Blanchfield and Mannie, 
2010; Kim et al., 1997; Maecker et al., 2001; Maecker et al., 2001; Mannie and Abbott, 
2007; Mannie et al., 2007a). Cytokine fusion proteins target antigen to specific antigen 
presenting cell populations (Mannie et al., 2007b; Blanchfield and Mannie, 2010), 
upregulate T Regulatory cells (Mannie et al., 2007b), bias the immune system toward 
TH1 responses (Kim et al., 1997; Maecker et al., 2001), and induce immunological 
tolerance to antigen (Mannie et al., 2007b; Blanchfield and Mannie, 2010). Cytokines 
involved in asthma pathogenesis include the TH2-specific cytokines - IL-4, IL-5, and IL-
13 - as well as general cytokine growth factors such as IL-2, a growth factor for 
lymphocytes, and GM-CSF, a growth factor for neutrophils, eosinophils, and basophils 
(Mannie et al., 2007b; Blanchfield and Mannie, 2010). While IL-4, IL-5, and IL-13 are 
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recognized as key cytokines in asthma processes and may warrant future cytokine 
fusion projects, GM-CSF is equally involved. Upon exposure of DC and macrophage 
APC cytokine receptors to specific signals such GM-CSF, APC are more inclined to 
develop a tolerogenic state, leading to the deletion or anergization of reactive T cells 
(Kapsenberg, 2003) or the induction of suppressive TRegs (Ganesh et al., 2009; 
Dhodapkar et al., 2001). In addition, GM-CSF has been implicated in the targeting and 
differentiation of dendritic cell and macrophage antigen presenting cells and has 
demonstrated the potential to induce immunological tolerance (Mannie et al., 2007b; 
Blanchfield and Mannie, 2010). As many murine asthma models use ovalbumin to 
induce allergic inflammation, OVA 323-339, the primary antigenic domain of ovalbumin, 
could thus be targeted to DC and macrophage APC populations in an effort to tolerize 
the immune system and reverse asthma symptoms. The objective of this study was to 
test the hypothesis that fusion proteins comprised of GM-CSF and OVA 323-339 
epitopes potentiate antigen-specific immunological tolerance and attenuate 
development of asthma. The hypothesis was tested using OVA-sensitive mice and 
GMCSF-OVA 323-339 fusion proteins. The following specific aims will be pursued: 
Specific Aims 
Aim 1: Establish the efficacy of the GMCSF-OVA 323-339 cytokine-fusion protein in 
vitro 
Fusion products were generated through the melding of OVA 323-339 to GM-
CSF sequences using PCR with appropriate templates and primers. The biological 
activity of fusion protein cytokine domains were assessed by incubating respective 
supernatants with rat bone marrow cells pulsed with tritiated thymidine ([3H]thymidine). 
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Cell growth and proliferation of mouse bone marrow cells due to the presence of GM-
CSF was measured via [3H]thymidine incorporation. The biological activity of fusion 
protein antigenic domains was validated by addition of protein to splenic cell cultures 
derived from C57BL/6-Tg(TcraTcrb) (OT-II.2) mice, containing OVA-reactive T Cell 
repertoires, incubated with [3H]thymidine. As with the cytokine domain bioassay, T Cell 
clonal expansion due to OVA 323-339 was measured via [3H]thymidine incorporation in 
samples. 
Aim 2: Develop a murine asthma model for testing of the cytokine-fusion protein 
A successful model of ovalbumin-induced inflammation in mice was essential for 
verifying the efficacy of the cytokine fusion protein vaccine. OVA-sensitized and 
challenged animal groups were tested for airway and lung inflammation, IL-4, 5, and 13, 
and IgE, IgG1 compared to saline controls.  
Aim 3: Verify the efficacy of the GMCSF-OVA 323-339 cytokine-fusion protein in vivo 
Using a model of ovalbumin-induced inflammation in mice, the cytokine fusion 
protein vaccine was tested for ability to attenuate OVA-induced increases in airway and 
lung inflammation, increases in IL-4, 5, and 13, and increases in levels of IgE and IgG1.  
Study Justification 
The approach of the study was novel with respect to fusion-protein-induced 
tolerance in an asthma model, but was a refinement of an existing model and research 
conducted by Mannie et al. using an experimental autoimmune encephalitis (EAE) 
model for Multiple Sclerosis (Mannie et al., 2007b; Blanchfield and Mannie, 2010; 
Mannie and Abbott, 2007; Mannie et al., 2007a). Multiple Sclerosis is an immune-
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system-mediated disease involving an initial error within the antigen presentation 
pathway. As immunological tolerance to myelin basic protein was induced in EAE 
models through administration of cytokine fusion proteins (Mannie et al., 2007b; 
Blanchfield and Mannie, 2010; Mannie and Abbott, 2007; Mannie et al., 2007a), 
immunological tolerance to OVA 323-339 in the mouse model of asthma may be 
likewise induced through use of fusion proteins. Research by Umetsu et al., has 
demonstrated the ability for cytokine fusion protein and fusion DNA to precipitate a shift 
from a TH2 to a TH1 immunophenotype in mice (Kim et al., 1997; Maecker et al., 2001; 
Maecker et al., 1997). While the focus of this study was to prevent asthma-like 
inflammation rather than to skew the TH response, documentation that such fusion 
proteins have the capacity to effect immunological change in an asthma model provides 
support that proposed immunological tolerance may be induced in this study. The 
demonstrated ability of fusion proteins to alter immune system balance in mice provides 
evidence that this approach may be effective in returning the immune system to 
homeostasis within an asthma model. 
With regard to the choice of species for the asthma model, the mouse was 
deemed the best candidate for the study. Firstly, all research must begin with a lower-
order model as a basis, and due to the fact that this study is proof-of-concept in nature, 
the mouse is a suitable vehicle for experimentation. In addition, many investigators have 
used murine models to study asthma and pulmonary allergic inflammation. Finally, the 
use of mouse model has distinct advantages including ease of manipulation, availability 
of transgenics for immunomodulation, as well as the multitude of commercially available 
murine-specific reagents necessary for experimentation. For this study, particularly due 
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to the availability of OVA 323-339-reactive transgenics, mice were chosen as the 
vehicle in which to test the GMCSF-OVA 323-339 fusion protein. 
  
CHAPTER 2: EFFICACY OF THE GMCSF-OVA 323-339 CYTOKINE FUSION 
PROTEIN IN VITRO 
 
Introduction 
The production of the cytokine-antigen fusion proteins and assurance of their 
functionality in vitro is a critical initial step toward investigating their use as a therapeutic 
tool within an animal model. One of the challenges in the production of cytokine fusion 
proteins is the size of the proteins themselves. The fusion of an entire protein such as 
ovalbumin to a cytokine domain, for example, if even possible, would be a difficult 
undertaking. It is for this reason that OVA 323-339, the most antigenic epitope of 
ovalbumin, was chosen to create the fusion proteins and thus chosen for animal 
sensitization and challenge in the model. Another challenge is to ensure that fusion 
proteins retain bioactivity for both the cytokine and the antigenic domain, and that 
bioactivity is neither lost nor altered due to the fusion of the two original proteins. The 
bioactivity can be measured through specific assays for each individual domain, and in 
this way, protein functionality is ensured. For Specific Aim 1 of this project, cytokine-
OVA 323-339 fusion proteins were generated and tested using a variety of in vitro 
systems. 
Methods 
Fusion DNA design 
 Two GM-CSF-based fusion proteins (GMCSF-OVA 323-339 and GM-CSF) were 
used in this study. The GMCSF-OVA 323-339 fusion protein contained an N-terminal 
mature mouse GM-CSF domain linked to a 17 amino acid C-terminal domain comprised 
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of the predominant antigenic domain of OVA (I-S-Q-A-V-H-A-A-H-A-E-I-N-E-A-G-R) 
coupled to six H residues for protein purification. We also expressed a GM-CSF fusion 
protein without the antigenic OVA peptide and directly coupled to the six C-terminal H 
residues. The mouse GM-CSF domain of both fusion proteins was based on a complete 
mouse mRNA sequence and encoded the mature mouse GM-CSF cytokine.  
 The mouse GM-CSF sequence was inserted by standard PCR techniques to 
allow for proper translation and secretion of the fusion proteins. In the first round of 
PCR, pVAX GM-CSF was used with forward and reverse primers to amplify the cytokine 
sequence from the pVAX vector. In the second round of PCR, GM-CSF-specific forward 
primer and OVA 323-339 reverse primer were added to the PCR round 1 GMCSF-OVA 
323-339 product. GM-CSF-specific forward and reverse primers contained added 
overlaps for insertion into parental plasmid added to PCR round 1 GMCSF-only product. 
In PCR round 3, GMCSF- and OVA 323-339-specific forward and reverse primers 
containing added overlaps for insertion into parental plasmid were added to the PCR 
round 2 GMCSF-OVA 323-339 product. In the PCR round 4, the GM-CSF-only product 
from PCR round 2 and GMCSF-OVA 323-339 product from PCR round 3 were inserted 
into a pIRES2-AcGFP1 parental plasmid, a mammalian vector containing an internal 
ribosomal entry site, Aequorea coerulescens green fluorescent protein, and a 
kanamycin/neomycin resistance gene. Products generated were designated as follows: 
GM-CSF.18, GMCSF-OVA 323-339.21. Plasmid DNA was then washed to remove salts 
with the OriGene® PowerPrep™ HP Plasmid Midiprep Kit with Prefilters. In PCR round 
5, methylated pIRES2-AcGFP1 plasmids (original, non-insert-containing plasmids) were 
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digested with restriction endonucleases. Plasmids were washed a second time, and gel 
electrophoresis confirmed that constructs were the correct length. 
Fusion DNA expression and purification 
 GMCSF-OVA 323-339 and GM-CSF DNA constructs made via PCR were 
transformed into Top10 E. Coli bacteria using a BioRad MicroPulser™. Construct-
containing bacteria were streaked onto Luria Bertani (10 g tryptone, 10 g NaCl, 5 g 
yeast extract, 950 mL deionized H2O) agar plates containing 50 μg/mL kanamycin 
(Gemini Bio-Products, West Sacramento, CA). Nine individual colonies were selected 
and grown for each construct. Colonies were designated a-i as follows: GM-CSF.18 a-i, 
and GMCSF-OVA 323-339.21 a-i. Individual colonies were harvested and expanded in 
Luria Bertani broth supplemented with kanamycin. Glycerol stocks generated from each 
expanded colony (GM-CSF.18 a-i, and GMCSF-OVA 323-339.21 a-i) were prepared 
and frozen at -80°C. Fusion DNA plasmids were extracted from transformed Top10 E. 
Coli bacterial cultures and purified using the OriGene® PowerPrep™ HP Plasmid 
Midiprep Kit with Prefilters. Gel electrophoresis confirmed the presence and length of 
fusion DNA constructs. DNA for select constructs (GM-CSF.18b and c, and GMCSF-
OVA 323-339.21b and c) was sequenced. All sequences were perfect or likely-perfect 
with the exception of GM-CSF.18c.  
Fusion protein expression, purification, and quantitation 
 DNA constructs were transfected into a healthy 293F Human Embryonic Kidney 
(HEK) cell line using TurboFect cationic polymer (Fermentas, catalog # RO531). A 
stable line was generated from successfully transfected cells, and transfection success 
and stable line efficiency was confirmed via flow cytometry. Protein secreted in 
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supernatant from spinner flasks containing the GMCSF-OVA 323-339-expressing 293F 
HEK cell line was collected and frozen at -20°C. Supernatants were then pooled and 
concentrated by Amicon® Stirred Ultrafiltration Cells and YM3 membranes (3 kDa 
exclusion; Millipore, Billerica, MA, USA). Concentrated protein was purified by use of 
nickel-columns (Ni-NTA Superflow Nickel beads, Qiagen GmbH - Hilden, Germany; 
Poly-Prep Chromatography Columns, BioRad - Hercules, CA, USA) to bind the 
GMCSF-OVA 323-339 C-terminal histidine tail. Nickel-column elution fractions were 
subjected to SDS-PAGE, then silver-stained to confirm protein molecular weight (GM-
CSF, ~17.4 kDa; GMCSF-OVA 323-339, ~19.1 kDa). Elution buffer was exchanged for 
PBS using an Amicon® Ultra-15 Centrifugal Filter Device (3 kDa), and protein was 
quantitated by use of a NanoDrop® ND-1000 Spectrophotometer. 
Measurement of fusion protein bioactivity 
 To measure fusion protein cytokine domain bioactivity, fresh bone marrow cells 
from SJL mice (100,000 cells/well) were cultured with complete RPMI and 100 nM 
GMCSF-OVA 323-339 or GM-CSF fusion protein. Cultures were pulsed with 1 μCi 
[3H]thymidine (6.7 Ci/mmol, New England Nuclear, Perkin Elmer, Waltham, MA, USA) 
on day 3, and harvested onto filter-mats on day four with a Tomtec Mach III harvester 
(Hamden, CT, USA). [3H]Thymidine incorporation into DNA was measured using a 
Wallac 1450 Microbeta Plus liquid scintillation counter (Perkin Elmer). Figure error bars 
represent the standard error of triplicate sample wells. 
 To measure fusion protein antigenic domain bioactivity, OVA 323-339-specific T 
cell responders (25,000 cells/well) were cultured with irradiated (3000 rads) splenocytes 
(500,000 cells/well) from wild-type C57BL/6J mice in complete RPMI and 1 μM GMCSF-
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OVA 323-339 or GM-CSF fusion protein, or OVA 323-339 peptide. Cultures were 
pulsed with [3H]thymidine and harvested as described for cytokine domain bioactivity 
assays above. 
FACS analysis 
 To determine transfection and stable line efficiency, FACS analysis was 
performed on cell samples. The pIRES2-AcGFP1 vectors containing the inserted fusion 
DNA contain a reporter AcGFP1 sequence downstream of the GMCSF-OVA 323-339 
sequence, allowing successfully transfected 293F HEK cells to fluoresce in the FITC 
window. Data were acquired with a Becton Dickinson FACScan flow cytometer and 
were analyzed with the FloJo software program. Dead cells were excluded from 
analysis by gating forward versus side scatter plots. 
Animals 
OT-II.2 (B6.Cg-Tg(TcraTcrb)425Cbn/J) mice (Jackson Labs, Bar Harbor, ME, 
USA), C57BL/6J mice, and SJL mice were bred and housed at the East Carolina 
University Brody School of Medicine (Greenville, NC, USA). Animal care and use were 
performed in accordance with animal use protocols and institutional guidelines 
approved by the East Carolina University Institutional Animal Care and Use Committee. 
Cell lines and culture conditions 
The OT-II.2 memory T cell line was an IL-2-dependent line derived from OT-II.2 
mouse splenocytes incubated with 1 μM OVA 323-339 peptide at 37°C, 5% CO2. This T 
cell line was cultured in complete RPMI medium [10% heat-inactivated FBS, 2 mM 
glutamine, 100 μg/mL streptomycin and 100 U/mL penicillin (Whittaker Bioproducts, 
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Walkersville, MD, USA)] supplemented with rat rIL-2 (0.4% v/v Sf9 supernatant). The 
cell line was maintained by periodically stimulating proliferation and line expansion by 
incubating the OVA-specific T cells with 1 μM OVA 323-339 and irradiated mouse 
splenocytes to serve as antigen presenting cells in the culture. The OVA 323-339-
specific T cell line was maintained at 37°C, 5% CO2.    
The 293F HEK cell line was cultured in Freestyle™ 293 Expression Medium 
(Gibco®, Grand Island, NY, USA) at 37°C, 5% CO2. The GMCSF-OVA 323-339-
expressing 293F HEK cell line was derived from 293F HEK cells stably transfected with 
GMCSF-OVA 323-339. The 293F HEK-derived line was cultured in Freestyle™ 293 
Expression Medium and 400 μg/mL Geneticin (Gemini Bio-Products, West Sacramento, 
CA) to select for genetically manipulated cells possessing Geneticin resistance 
conferred by the introduced plasmid. Culture was maintained at 37°C, 5% CO2.  
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Results and Discussion 
The most important result of this study was the successful generation of GMCSF-
OVA 323-339 cytokine fusion constructs. Although IL-2, IL2-OVA 323-339, IFN-β, IFNβ-
OVA 323-339, and GM-CSF constructs were also generated, as the project focused on 
the GMCSF-OVA 323-339 fusion protein, the GMCSF-OVA 323-339 fusion was 
carefully assessed. The cytokine domain of GMCSF-OVA 323-339 purified protein was 
shown to have biological activity similar to that of the GM-CSF positive control, and that 
antigenic domain bioactivity was intact as well. Taken together, the GMCSF-OVA 323-
339 may be described as a fully functional protein with neither domain affected by 
fusion to the other. It was concluded that GMCSF-OVA 323-339 fusion proteins met 
functionality criteria for further experimentation in vivo. 
 An overview of the fusion construct DNA generation is shown in figure 2.1, and a 
detailed representation of the GMCSF-OVA 323-339 vector is shown in figure 2.2. IL-2, 
IL2-OVA 323-339, IFN-β, IFNβ-OVA 323-339, GM-CSF, and GMCSF-OVA 323-339 
cytokine fusion constructs were generated via PCR and run on gel electrophoresis to 
ensure constructs matched the expected size as compared to Invitrogen TrackIt 100 bp 
DNA Ladder (figure 2.4). Of samples IL-2.16 a-i, IFNβ.17 a-i, GM-CSF.18 a-i, IL2-OVA 
323-339.19 a-i, IFNβ-OVA 323-339.20 a-i, and GMCSF-OVA 323-339.21 a-i, all were 
the correct size with the exception of IL-2.16a, IFNβ.17d, GM-CSF.18f, GM-CSF.18i, 
IFNβ-OVA 323-339.20h, GMCSF-OVA 323-339.21a, and GMCSF-OVA 323-339.21g. 
Constructs of the correct size were transformed into Top10 E. Coli and frozen as 
glycerol stocks for use in transfections for protein expression (figure 2.3).  
 55 
 Small-scale transfections with select IL-2, IL2-OVA 323-339, IFN-β, IFNβ-OVA 
323-339, GM-CSF, and GMCSF-OVA 323-339 constructs were performed to determine 
the presence of functional cytokine domain biological activity in transfection 
supernatants (figure 2.5). 293 F HEK cells (75,000 cells per well) were transfected with 
IL-2 (16b, c, d, e), IL2-OVA 323-339 (19a, b, c, d), IFNβ (17a, b, c, e), IFNβ-OVA 323-
339 (20a, b, c, d), GM-CSF (18a, b, c, d), and GMCSF-OVA 323-339 (21b, c, d, e) in 
96-well plates, and supernatants were collected after 72 hours. Supernatants were 
added in half-log dilutions to cell lines in 96-well plates: IL-2 and IL2-OVA 323-339 
supernatants were incubated with CTLL-2 cells (IL-2 dependent cells), IFN-β and IFNβ-
OVA 323-339 supernatants were incubated with BW5147 cells (T-lymphocytes; cells die 
with increased concentrations of IFN-β), and GM-CSF and GMCSF-OVA 323-339 
supernatants were incubated with SJL BMCs (cells proliferate in the presence of GM-
CSF), 10,000 cells per well, each. Plates were pulsed with 1 μCi [3H]thymidine on day 
3, and harvested onto filter-mats on day 4 with a Tomtec Mach III harvester. 
[3H]Thymidine incorporation into DNA was measured as counts per minute (CPM) using 
a Wallac 1450 Microbeta Plus liquid scintillation counter. Increases in CPM were 
indicative of cell proliferation. 
 Of the samples tested, IL2.16c and b, IL2-OVA 323-339.19b and c, IFNβ.17c and 
e, IFNβ-OVA 323-339.20c and a, GMCSF.18c and b, and GMCSF-OVA 323-339.21b 
and c, had the most active cytokine domains. The presence of cytokine domain 
biological activity suggested that cytokine fusion constructs were likely functional and 
could be used for large-scale transfections and protein production. 
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 Large-scale transfections using 293 HEK cells and plasmids from appropriate 
GMCSF-OVA 323-339 constructs generated a stable GMCSF-OVA 323-339-producing 
cell line. To evaluate the success of the transfection and the protein-producing 
capabilities of the cell line, cellular AcGFP1 expression was evaluated via flow 
cytometry (figure 2.6). 1 x 106 cells were sampled from the 293F HEK + GMCSF-OVA 
323-339 stably transfected cell line and placed into tubes for flow-cytometric analysis. 
AcGFP1 expression (denoted by FITC-A) data were acquired with a Becton Dickinson 
FACScan flow cytometer. The majority of dead cells were excluded from analysis by 
gating forward versus side scatter plots. Elevated numbers of FITC-A-bright cells 
suggested a successfully transfected 293F HEK + GMCSF-OVA 323-339 stable line 
and a good probability for high protein yield.  
 To determine the protein-production ability of the stable GMCSF-OVA 323-339-
producing cell line, spinner flasks were heavily-seeded with 293F HEK + GMCSF-OVA 
323-339 cells in EM medium. Supernatants were collected for 5 sequential days, and all 
cells were re-seeded into flasks with fresh EM medium and 400 μg/mL Geneticin daily. 
Flasks contained ~30 x 106 cells/mL on supernatant collection day 1; cells were allowed 
to grow, unrestricted, through day 5. Flasks were discarded after the day 5 supernatant 
collection. 
 Supernatants were concentrated using an Amicon Stirred Ultrafiltration Cell and 
a YM3 membrane, purified using a Nickel column, run on SDS-PAGE gel, then silver-
stained to determine protein purity (see figure 2.7). Bands visible in lanes 9 and 10 
occur due to protein glycosylation sites. Protein was quantified via NanoDrop ND-1000 
Spectrophotometer following buffer exchange (250 mM Imidazole exchanged for PBS) 
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using an Amicon Ultra-15 Centrifugal Filter Device with 3K membrane. Protein yields 
were as high as 936 μg for the expression system when using four spinner flasks. 
In order to determine GMCSF-OVA 323-339 antigenic domain bioactivity and 
responsiveness compared to OVA 323-339, a memory T cell line was derived from OT-
II.2 mouse splenocytes (figure 2.8). Naive OT-II.2 mouse splenocytes (5 x 106 cells/10 
mL cRPMI, no IL-2) were cultured with 1 μM OVA 323-339 for 3 days. Cells were 
supplemented with 0.3162% IL-2 (v/v) in complete RPMI. Flasks were observed and 
passaged on day 6. On day 10, cell line was centrifuged and washed with HBSS to 
remove IL-2 from culture, then cells were plated (25,000 cells/well) in 96-well plates with 
irradiated (3,000 rads) C57BL/6J splenocytes to serve as APC (250,000 cells/well) and 
1-log dilutions of OVA 323-339 from 10 μM to 10 pM. Plates were pulsed with 1 μCi 
[3H]thymidine on day 13, and harvested onto filter-mats on day 14 with a Tomtec Mach 
III harvester. [3H]Thymidine incorporation into DNA was measured using a Wallac 1450 
Microbeta Plus liquid scintillation counter. The OT-II.2 memory T cell line was active and 
responsive to OVA 323-339 as evidenced by the increased CPM, and so, OT-II.2 
memory T cell proliferation, corresponding with increasing concentrations of OVA 323-
339 in figure 2.8. 
 GMCSF-OVA 323-339 antigenic domain bioactivity was evaluated in comparison 
to OVA 323-339 bioactivity with OT-II.2 mouse splenocytes (figure 2.9A) and with OT-
II.2 mouse-derived memory T cell line (figure 2.9B). In 2.9A, OT-II.2 mouse splenocytes 
were harvested and plated (230,000 cells per well) in a 96-well plate with 1-log dilutions 
of whole OVA, OVA 323-339, GMCSF-OVA 323-339, or GM-CSF (0.5 μM to 0.5 pM) in 
complete RPMI. In 2.9B, OVA 323-339-specific T cell responders (25,000 cells/well) 
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were cultured with irradiated (3000 rads) splenocytes (500,000 cells/well) from wild-type 
C57BL/6J mice in a 96-well plate with 1-log dilutions of GMCSF-OVA 323-339 peptide, 
GM-CSF fusion protein, or OVA 323-339 peptide (1 μM to 1 pM) in complete RPMI. 
Cultures were pulsed with 1 μCi [3H]thymidine on day 3, and harvested onto filter-mats 
on day 4 with a Tomtec Mach III harvester. [3H]Thymidine incorporation into DNA was 
measured using a Wallac 1450 Microbeta Plus liquid scintillation counter. 
 The antigenic domain of the GMCSF-OVA 323-339 purified protein was shown to 
be biologically active. GMCSF-OVA 323-339 cultured with naïve splenocytes from OT-
II.2 mice attenuated T cell proliferation compared to naïve splenocytes cultured with 
OVA 323-339, while whole OVA and GM-CSF had no effect on T cell proliferation. In 
contrast, GMCSF-OVA 323-339 cultured with cells from the memory OT-II.2 T cell line 
caused antigenic domain bioactivity to be left-shifted compared with the OVA 323-339 
positive control, suggesting targeting of antigen to T cell responders. 
 GMCSF-OVA 323-339 cytokine domain bioactivity was evaluated in comparison 
to GM-CSF bioactivity using SJL mouse bone marrow cells (figure 2.10). In figure 2.10, 
SJL bone marrow cells (cell line; 10,000 cells per well) were cultured in a 96-well plate 
with 0.5-log dilutions of GMCSF-OVA 323-339, rat GM-CSF, mouse GM-CSF, or 
GMCSF-MOG fusion protein (1 nM to 100 fM) in complete RPMI. The culture was 
pulsed with 1 μCi [3H]thymidine on day 3, and harvested onto filter-mats on day 4 with a 
Tomtec Mach III harvester. [3H]Thymidine incorporation into DNA was measured using 
a Wallac 1450 Microbeta Plus liquid scintillation counter. The cytokine domain of 
GMCSF-OVA 323-339 purified protein was shown to have biological activity similar to 
that of the GM-CSF positive control. Taken together with the antigenic domain 
 59 
bioactivity data, the GMCSF-OVA 323-339 may be described as a fully functional 
protein with neither domain affected by fusion to the other. Given that the cytokine 
fusion protein was successfully generated and shown to have appropriate bioactivity in 
both the cytokine and antigenic domains, the fusion protein is suitable for testing in an 
animal model to determine its potential for altering the immune response to the OVA 
323-339 antigen. 
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Tables and Figures 
Figure 2.1. Overview of GMCSF-OVA 323-339 fusion DNA production  
Two GM-CSF-based fusion proteins (GMCSF-OVA 323-339 and GM-CSF) were used 
in this study. The mouse GM-CSF sequence was inserted by standard PCR techniques 
to allow for proper translation and secretion of the fusion proteins, and gel 
electrophoresis confirmed that constructs were the correct length. GMCSF-OVA 323-
339 and GM-CSF DNA constructs made via PCR were transformed into Top10 E. Coli 
bacteria. Construct-containing bacteria were streaked onto Luria Bertani agar plates 
containing 50 μg/mL kanamycin, and individual colonies were selected and grown for 
each construct. Colonies were harvested and expanded in Luria Bertani broth 
supplemented with kanamycin. Glycerol stocks generated from each expanded colony 
were prepared and frozen at -80°C. Fusion DNA plasmids were extracted from 
transformed Top10 E. Coli bacterial cultures and purified using the OriGene® 
PowerPrep™ HP Plasmid Midiprep Kit with Prefilters. Gel electrophoresis confirmed the 
presence and length of fusion DNA constructs, and DNA for select constructs was 
sequenced.  
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Figure 2.2. General design of the cytokine-OVA 323-339 fusion construct 
An overview of the GMCSF-OVA 323-339 fusion construct design. Major components 
include the murine GM-CSF cytokine domain followed immediately by the OVA 323-339 
antigenic domain, and the downstream AcGFP1 sequence and histidine tail. 
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Figure 2.3. Overview of GMCSF-OVA 323-339 fusion protein production 
DNA constructs were transfected into a healthy 293F Human Embryonic Kidney (HEK) 
cell line. Transfection success and efficiency was confirmed via flow cytometry. Protein 
secreted in supernatant from spinner flasks containing the GMCSF-OVA 323-339-
expressing 293F HEK cell line. Supernatants were then pooled and concentrated using 
Ultrafiltration Cells. Concentrated protein was purified by use of nickel-columns to bind 
the GMCSF-OVA 323-339 C-terminal histidine tail. Nickel-column elution fractions were 
subjected to SDS-PAGE, then silver-stained to confirm protein molecular weight. Elution 
buffer was exchanged for PBS, and protein was quantitated via Spectrophotometer. 
Fusion protein cytokine and antigenic domain bioactivity was then assessed using 
bioassays. 
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Figure 2.4. Generation of IL-2, IL2-OVA 323-339, IFN-β, IFNβ-OVA 323-339, GM-
CSF, and GMCSF-OVA 323-339 cytokine fusion constructs 
IL-2, IL2-OVA, IFN-β, IFNβ-OVA, GM-CSF, and GMCSF-OVA 323-339 cytokine fusion 
constructs were generated via PCR and run on gel electrophoresis to ensure constructs 
matched the expected size (IL-2: 666 bp, IL2-OVA: 703 bp, IFN-β: 726 bp, IFNβ-OVA: 
763 bp, GM-CSF: 582 bp, and GMCSF-OVA 323-339: 619 bp) as compared to 
Invitrogen TrackIt 100 bp DNA Ladder (*). Of samples IL-2.16 a-i, IFNβ.17 a-i, GM-
CSF.18 a-i, IL2-OVA 323-339.19 a-i, IFNβ-OVA 323-339.20 a-i, and GMCSF-OVA 323-
339.21 a-i, all were the correct size with the exception of IL-2.16a, IFNβ.17d, GM-
CSF.18f, GM-CSF.18i, IFNβ-OVA 323-339.20h, GMCSF-OVA 323-339.21a, and 
GMCSF-OVA 323-339.21g. 
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Figure 2.5. Cytokine domain bioactivity of IL-2, IL2-OVA 323-339, IFN-β, IFNβ-OVA  
323-339, GM-CSF, and GMCSF-OVA 323-339 cytokine fusion supernatants 
293 F HEK cells were transfected with IL-2 (16 b, c, d, e), IL2-OVA 323-339 (19 a, b, c, 
d), IFN-β (17 a, b, c, e), IFNβ-OVA 323-339 (20 a, b, c, d), GM-CSF (18 a, b, c, d), and 
GMCSF-OVA 323-339 (21 b, c, d, e) samples, and supernatants collected after 72 
hours. Supernatants were added in half-log dilutions to cell lines in 96-well plates: IL-2 
and IL2-OVA 323-339 supernatants were incubated with CTLL-2 cells, IFN-β and IFNβ-
OVA 323-339 supernatants were incubated with BW5147 cells, and GM-CSF and 
GMCSF-OVA 323-339 supernatants were incubated with SJL BMCs. Plates were 
pulsed with 1 μCi [3H]thymidine on day 3, and harvested onto filter-mats on day 4 with a 
Tomtec Mach III harvester. [3H]Thymidine incorporation into DNA was measured using 
a Wallac 1450 Microbeta Plus liquid scintillation counter. Error bars represent the 
standard error for values obtained in replicate wells in the assay. 
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Figure 2.6. A flow-cytometric assessment of AcGFP1 expression in the 293F HEK 
+ GMCSF-OVA 323-339 stably-transfected cell line 
1 x 106 cells were sampled from the 293F HEK + GMCSF-OVA 323-339 stably 
transfected cell line for flow-cytometry. Cellular AcGFP1 expression is denoted by the 
FITC-A stain. When expressed, AcGFP1, located downstream of GMCSF-OVA 323-339 
in the fusion construct, serves as an indicator of GMCSF-OVA 323-339 production and 
expression and thus, efficiency of the stably transfected cell line. Flow cytometry data 
and graph was gated on live cells (P1). P2 represents the GFP+ population within P1. 
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Figure 2.7. Determination of GMCSF-OVA 323-339 protein purity 
Supernatants collected from the stably-transfected 293F HEK + GMCSF-OVA 323-339 
cell line were concentrated and purified, run on SDS-PAGE gel, then silver-stained to 
determine protein purity (GMCSF-OVA 323-339 = 19.1 kDa). Lane 1: Fermentas 
SpectraTM Multicolor Broad Range Protein Ladder; lanes 2-8: flow-through solutions 
collected during protein concentration and purification; lane 9: Nickel Column GMCSF-
OVA 323-339 elution #1/4; lane 10: Nickel Column GMCSF-OVA 323-339 elution #2/4. 
Bands visible in lanes 9 and 10 occur due to GMCSF-OVA 323-339 glycosylation sites. 
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Figure 2.8. OT-II.2 mouse-derived memory T cell line efficacy 
Memory OT-II.2 T Cell Line was derived by culturing naive OT-II.2 mouse splenocytes 
with 1 μM OVA 323-339 for 3 days. Cells were then supplemented with 0.3162% IL-2 
(v/v) in complete RPMI. Cells were washed to remove IL-2 from medium, then plated in 
96-well plates with irradiated C57BL/6J splenocytes and 1-log dilutions of OVA 323-339 
from 10 μM to 10 pM. Plates were pulsed with 1 μCi [3H]thymidine on day 13, and 
harvested onto filter-mats on day 14 with a Tomtec Mach III harvester. [3H]Thymidine 
incorporation into DNA was measured using a Wallac 1450 Microbeta Plus liquid 
scintillation counter. Error bars represent the standard error for values obtained in 
replicate wells in the assay. 
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Figure 2.9. OT-II.2 T Cell proliferative response to GMCSF-OVA 323-339 compared 
with OVA 323-339 and GM-CSF 
In 2.9A, OT-II.2 mouse splenocytes were harvested and plated with 1-log dilutions of 
whole OVA, OVA 323-339, GMCSF-OVA 323-339, or GM-CSF (0.5 μM to 0.5 pM) in 
complete RPMI. In 2.9B, cells from the Memory OT-II.2 T Cell Line were cultured with 
irradiated splenocytes from wild-type C57BL/6J mice and 1-log dilutions of GMCSF-
OVA 323-339 peptide, GM-CSF fusion protein, or OVA 323-339 peptide (1 μM to 1 pM) 
in complete RPMI. For both 2.9A and 2.9B, cultures were pulsed with 1 μCi 
[3H]thymidine on day 3, and harvested onto filter-mats on day 4 with a Tomtec Mach III 
harvester. [3H]Thymidine incorporation into DNA was measured using a Wallac 1450 
Microbeta Plus liquid scintillation counter. Error bars represent the standard error for 
values obtained in replicate wells in the assay. 
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Figure 2.10. SJL bone marrow cell proliferative response to GMCSF-OVA 323-339 
cytokine domain compared with GM-CSF 
SJL BMCs (cell line; 10,000 cells per well) were cultured in a 96-well plate with 0.5-log 
dilutions of GMCSF-OVA 323-339, rat GM-CSF, mouse GM-CSF, or GMCSF-MOG 
fusion protein (1 nM to 100 fM) in complete RPMI. The culture was pulsed with 1 μCi 
[3H]thymidine on day 3, and harvested onto filter-mats on day 4 with a Tomtec Mach III 
harvester. [3H]Thymidine incorporation into DNA was measured using a Wallac 1450 
Microbeta Plus liquid scintillation counter. Error bars represent the standard error for 
values obtained in replicate wells in the assay. 
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Conclusion 
IL-2, IL2-OVA 323-339, IFN-β, IFNβ-OVA 323-339, GM-CSF, and GMCSF-OVA 
323-339 cytokine fusion constructs were successfully generated, and small-scale 
transfections were performed with these constructs. Functional cytokine domain 
biological activity assessed, and of the samples tested, IL2.16c and b, IL2-OVA 323-
339.19b and c, IFNβ.17c and e, IFNβ-OVA 323-339.20c and a, GMCSF.18c and b, and 
GMCSF-OVA 323-339.21b and c, had the most active cytokine domains. The presence 
of cytokine domain biological activity suggested that cytokine fusion constructs were 
likely functional and could be used for large-scale transfections and protein production. 
Large-scale transfections were then initiated on AcGFP1-positive populations, as 
AcGFP1 production was indicative of fusion protein production. Transfection 
supernatants were concentrated, purified, run on SDS-PAGE gel, then silver-stained to 
ensure protein purity. Protein was quantified via NanoDrop ND-1000 Spectrophotometer 
following buffer exchange, with protein yields were as high as 936 μg for the expression 
system when using four spinner flasks.  
Focusing on the GMCSF-OVA 323-339 fusion protein, antigenic domain 
bioactivity was assessed and shown to be biologically active. The cytokine domain of 
GMCSF-OVA 323-339 purified protein was shown to have biological activity similar to 
that of the GM-CSF positive control. Taken together with the antigenic domain 
bioactivity data, the GMCSF-OVA 323-339 may be described as a fully functional 
protein with neither domain affected by fusion to the other. Altogether, the fusion 
products were shown to be the correct sequence and the proteins were shown to be 
fully functional, even though an in vitro effect on OT-II.2 T cells could not be seen with 
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FACs analysis. It was concluded that GMCSF-OVA 323-339 fusion proteins should be 
tested in an in vivo system. 
  
CHAPTER 3: CONFIRMATION OF A MURINE MODEL OF ALLERGEN-INDUCED 
AIRWAY INFLAMMATION 
 
Introduction 
In order to test fusion protein efficacy, a suitable animal model is imperative, and 
a murine model of allergen-induced airway inflammation is an ideal option for a 
preliminary vehicle in which to test the fusion protein. Most murine models are 
ovalbumin-based (although house dust mite and other antigens have been reported for 
use in murine models), and while most ovalbumin-based models use whole ovalbumin 
for sensitization and challenge, GMCSF-OVA 323-339 fusion protein design made it 
necessary for OVA 323-339 to be used for both sensitization and challenge. Due to the 
fact that very few models use OVA 323-339 for both sensitization and challenge, it was 
necessary to pursue different protocols comparing the advantages of chronic vs. acute 
models, the use of a C57BL/6 vs. BALB/c mouse strains, the use of various adjuvants, 
sensitization routes, and challenge routes, as well as varying OVA 323-339 doses, and 
numbers of sensitizations and challenges. For Specific Aim 2 of this project, animal 
models of allergic inflammation were tested, and the success or failure of each protocol 
was evaluated based on its ability to produce pulmonary inflammation, particularly 
eosinophilic inflammation.  
Methods 
Animals 
BALB/c and C57BL/6 mice (Jackson Labs, Bar Harbor, ME, USA), were housed 
at the East Carolina University Brody School of Medicine (Greenville, NC, USA). Animal 
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care and use were performed in accordance with animal use protocols and institutional 
guidelines approved by the East Carolina University Institutional Animal Care and Use 
Committee. 
Animal model of pulmonary inflammation chosen for study 
 Active sensitization of mice with OVA 323-339 in Incomplete Freund's Adjuvant 
(IFA) was performed by subcutaneous injection of 200 μg OVA 323-339 in 200 μL IFA. 
Prior to sensitization injections, mice were anesthetized using isoflurane in a vented 
anesthetic chamber and injection sites were cleaned with povidone-iodine followed by 
an alcohol rinse. Sensitizations were performed on days 0, 7, and 14, and injection sites 
were monitored for signs of inflammation. Mice were challenged via pharyngeal 
aspiration (p.a.) on days 21, 22 and 23. The p.a. solution was 60 μL of 1% OVA-323-
339 in sterile saline, and was administered while mice were anesthetized with isoflurane 
in a vented anesthetic chamber. Control mice were given saline instead of the 1% OVA 
323-339 solution. Mice were harvested on day 26. 
Animal model of chronic pulmonary inflammation with pharyngeal aspiration 
sensitization and aerosol challenge 
 Mice were anesthetized with isoflurane and sensitized with either 75 μL 
phosphate buffered saline (PBS) or ovalbumin (OVA) + lipopolysaccharide (LPS) (100 
μg OVA + 0.1 μg LPS/75 μL) via oropharyngeal aspiration on days 0 and 6. Starting on 
day 13 mice were be exposed to a nose-only aerosol of either PBS or 2% OVA (no 
LPS) for 30 minutes for 3 consecutive days. Briefly, mice were placed in vented 
restraining tubes that were then placed with just the nose exposed to the inside of the 
aerosol chamber. PBS or OVA aerosols of respirable droplet size (1-10 μm) were 
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generated with a Devilbiss nebulizer and delivered to the chamber at 1 L/min for 30 
minutes. Three days of aerosol exposures were given at one-month intervals for three 
months. Three days after the final exposure, animals were harvested. 
Animal model of chronic pulmonary inflammation with intraperitoneal sensitization and 
aerosol challenge 
 Mice were sensitized on days 0 and 12 with 10 μg OVA 323-339 in 200 μL 
aluminum hydroxide (alum). Six days after the second sensitization, mice underwent six 
consecutive days of aerosol challenge (5% whole OVA in PBS or PBS alone) on days 
18-23 followed by two days of rest, then three added consecutive days (days 26-28) of 
aerosol challenge. During aerosol challenge, mice were placed in vented restraining 
tubes that were then placed with just the nose exposed to the inside of the aerosol 
chamber. PBS or OVA aerosols of respirable droplet size (1-10 μm) were generated 
with a Devilbiss nebulizer and delivered to the chamber at 1 L/min for 30 minutes. One-
third of the mice were sacrificed 24 hours after the day 28 aerosol challenge. Remaining 
mice were subjected to three consecutive days of aerosol challenge the following week 
on days 33-35, and another one-third of the mice were sacrificed 24 hours after the day 
35 aerosol challenge. The last one-third of the mice were given three aerosols per week 
for three weeks (days 40-42, 47-49, and 54-56), then sacrificed 24 hours after the day 
56 aerosol challenge. 
Animal model of acute pulmonary inflammation with intraperitoneal sensitization with 
OVA 323-339 in aluminum hydroxide and a single pharyngeal aspiration challenge 
 Mice were sensitized on days 0 and 12 with 10 μg OVA 323-339 in 200 μL alum 
via intraperitoneal injection. One week following the second sensitization, mice were 
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challenged with a single dose of 600 μg OVA 323-339 in 50 μL saline on day 19. Mice 
were sacrificed on day 21. 
Animal model of acute pulmonary inflammation with intraperitoneal sensitization with 
OVA 323-339 in aluminum hydroxide and a single pharyngeal aspiration challenge 
 Mice were sensitized on days 0, 7, and 14 with 200 μg OVA 323-339 in 200 μL 
alum via intraperitoneal injection. One week following the second sensitization, mice 
were challenged with 60 μL of a single dose of a 1% OVA 323-339 solution on days 21-
23. Mice were sacrificed on day 26. 
Pulmonary function testing 
 On the day of harvest, mice were anesthetized with tribromoethanol (250 mg/kg) 
and underwent tracheostomy. The tracheostomy was performed on anesthetized 
animals by making an incision through outer skin on the neck to create a 1 cm flap of 
skin exposing a small area of the throat, allowing the thyroid lobes to be divided bluntly 
at the isthmus and pulled aside. The muscle overlying the trachea was then removed 
with sterile scissors. Next, a small incision was made in the trachea just below the 
larynx, and a tracheal cannula (18g) was inserted and secured to the trachea with 3-0 
silk suture thread.  
Following cannula insertion, vecuronium bromide (0.2 mg/kg, i.p.) was 
administered to prevent interference of breathing patterns during lung function 
measurements.  Lung function measurements were made at baseline and at increasing 
concentrations of methacholine (MCh) aerosol: 0, 6.25, 12.5, 25, and 50 mg/ml MCh, to 
determine changes in airway resistance (R). Mice were euthanized via cardiac stick 
terminal bleed and pneumothorax immediately after lung function measurements, 
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bronchoalveolar lavage was performed to obtain lavage fluid, and tissues were collected 
for histological analysis. 
Serum collection 
 Terminal bleeds were performed via intracardiac puncture as a secondary means 
to ensure euthanasia as well as to collect serum samples. Whole blood collected from 
terminal bleeds was placed in serum separator tubes and centrifuged at 1,500 x g for 10 
minutes at 4˚C to obtain serum. Serum was collected for assay of cytokines and 
antibody titers, and to obtain cells for in vitro experimentation. Serum samples were 
stored at -80°C until assayed. 
Bronchoalveolar lavage (BAL)  
 Shortly following euthanasia, the chest cavity was opened and the left lung 
clamped for later removal for use in histology. Mice were then tracheostomized and 
cannulated, and BALs were performed on the right lung to obtain lavage fluid containing 
lung cells for differential cell counts. BALs were performed by introducing HBSS (26 
mL/kg body weight) into the right lung via a 1cc syringe, then withdrawing fluid through 
the cannula a total of four times in order to collect lung cells. 
Cytospins 
 BAL samples were centrifuged at 500 x g for 10 minutes at 4˚C. The cell pellet 
was resuspended in 0.5 mL HBSS, and cell counts performed. Volumes were adjusted 
and added for cytospin to allow for 20,000 cells per slide. The cytospin apparatus was 
run at 100 x g for 5 minutes, then slides were removed and allowed to dry. Once dry, 
slides were stained with H&E stain so that differential cell counts could be performed. 
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Differential cell counts 
 Differential cell counts were performed on stained cytospin slides from BAL 
samples to provide data on the cellular profile of the lung from which the sample was 
obtained. Three hundred cells per slide were identified and counted. Common cell types 
included monocytes, macrophages, neutrophils, eosinophils, lymphocytes, and 
epithelial cells. Elevations in certain types of cells (particularly eosinophils, neutrophils 
and lymphocytes) denoted inflammation. Statistical differences in group differential cell 
counts were determined with GraphPad Prism version 6. 
Cytokine analysis 
 Cytokine analysis was performed on serum samples with custom multiplex 
mouse cytokine ELISA kit, plate reader, and software from Meso Scale Discovery. 
ELISA was performed as instructed by the kit. Statistical differences in group cytokine 
expressions were determined with GraphPad Prism version 6. 
Histology 
 Following BAL collection from the right lung, the left lung was unclamped, inflated 
with 10% formalin, and stored in 10% formalin for 24-72 hours. Following fixation, the 
left lung was sectioned into thirds and placed in 70% ethanol for at least 24 hours. The 
left lung was then embedded in paraffin, cut into 5µm sections, mounted onto slides, 
and stained with Hematoxylin and Eosin (H&E). 
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Results and Discussion 
The key important finding from this study was the confirmation of a suitable 
animal model in which to test the GMCSF-OVA 323-339 fusion protein. Although 
pulmonary inflammation was not as prominent in this model as in others that use whole 
OVA for sensitization and/or challenge, inflammation was primarily eosinophilic, 
measurable, consistent, and significant (p<0.05, see figure 3.4). While this model 
cannot be classified as a true model of asthma due to the lack of airway response and 
the low-grade inflammation, likely a limitation of utilizing the 17-amino acid OVA peptide 
for both sensitization and challenge, it is a model of allergen-induced airway 
inflammation and is appropriate for the determination of GMCSF-OVA 323-339 anti-
inflammatory capabilities. 
As discussed previously with regard to the positive and negative aspects of the 
various animal models of asthma, it might be argued that the use of a murine model of 
asthma could have limited potential for real-world significance. While it is true that many 
asthma research related findings in mouse models have not translated into human 
clinical trials, all research must begin with a lower-order model as a basis, and due to 
the fact that this study is proof-of-concept in nature, the mouse is a suitable vehicle for 
experimentation. In addition, the use of a mouse model has distinct advantages 
including ease of manipulation, availability of transgenics for immunomodulation, as well 
as the multitude of commercially available murine-specific reagents necessary for 
experimentation. For this study, particularly due to the availability of OVA 323-339-
reactive transgenics, the mouse is an acceptable vehicle in which to test the GMCSF-
OVA 323-339 fusion protein. 
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The model development process presented difficulties due to the fact that various 
protocols attempted with OVA 323-339 for sensitization and challenge resulted in little 
or no inflammation. Protocol attempts included 1) chronic vs. acute models, 2) the use 
of a C57BL/6 strain vs. a BALB/c strain, 3) alum as an adjuvant vs. IFA, 4) pharyngeal 
aspiration vs. subcutaneous vs. intraperitoneal sensitization routes, 5) aerosol vs. 
pharyngeal aspiration challenge routes, as well as 6) varying OVA 323-339 doses and 
numbers of sensitizations and challenges (table 3.1). Early protocols attempts showed 
inflammation, but whole OVA had been used instead of OVA 323-339 for challenge 
(table 3.1, figure 3.2). Other model variations showed inflammation, but the 
inflammation was neutrophilic rather than eosinophilic in nature, and therefore not 
suitable as a model of typical allergic inflammation. Others yet resulted in no detectable 
inflammation whatsoever. The reasons underlying the difficulties encountered during 
model development may be explained by several factors.  
One factor that may have limited the development of a robust inflammatory 
response may have been the use of the OVA peptide for sensitization and challenge. 
Due to the fact the antigenic portion of the fusion protein was comprised of OVA 323-
339, it was decided that a model using OVA 323-339 for sensitization and challenge 
would be a best system in which to test the fusion proteins. The ability of the 17-amino 
acid peptide to elicit a robust response, however, might have contributed to the limited 
inflammatory responses observed in some of the model protocols. It is possible that the 
OVA peptide alone is not antigenically potent enough to induce an eosinophilic 
response equal to that seen with whole OVA in the literature.  
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Another factor that may have affected model development was the use of chronic 
aerosol exposure to recapitulate a more natural induction of pulmonary inflammation to 
parallel exposure routes in asthmatics. It is possible that a lack of inflammatory 
response in the attempted chronic aerosol models was due to underexposure, leading 
to a subpar inflammatory response, or overexposure, leading to a tolerance that has 
been observed in mouse asthma models due to the delivery of higher concentration of 
antigen or repeated exposures. Since it was not possible to determine the actual 
concentration of the aerosol in the exposure chamber or the ability of the nebulizer to 
evenly distribute the aerosol, aerosol delivery may have been a contributing factor. In 
addition, the animal restraints may have stressed the animals during the 30-minute 
exposures, which may have altered the immune response to antigen. Due to difficulties 
experienced with the chronic models, an acute model was chosen. 
Another issue that potentially affected model development was related to 
pharyngeal aspiration, as variability in antigen distribution can be introduced due to 
animal body position during dosing or due to smaller aspiration volumes, leading to 
variability in results or small localized areas of inflammation rather than evenly-
distributed general inflammation. Mice are anesthetized with isoflurane prior to 
pharyngeal aspiration, but must be dosed quickly due to the short-acting nature of the 
anesthetic. If mice are not completely vertical during dosing, the solution, when inhaled, 
may not be evenly distributed in both lungs. If too small a volume is used for aspiration, 
as may have been the case in earlier attempts based on other models, the distribution 
of solution containing antigen in the lungs may be uneven. Pharyngeal aspiration was 
preferred to inhalation as the delivery method due to the issues encountered with 
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aerosol exposures in the chronic models, though higher volumes (at least 60 μL) were 
chosen to allow for appropriate distribution of antigen and thus a more uniform 
response, thus aiding in the detection of inflammation in histological sections and 
differential cell counts. 
An additional factor that influenced the development of inflammation was mouse 
strain. Specifically, the development of eosinophilic rather than neutrophilic 
inflammation would have been affected by the strain of mouse used for a particular 
protocol. While C57BL/6 mice have been used successfully in pulmonary inflammation 
models in the literature, these mice tend to have a TH1-skewed immune response and 
therefore would not be as likely to develop the TH2-skewed inflammation sought after for 
this model. Data illustrating differences between BALB/c and C57BL/6 mouse 
pulmonary resistance, inflammation, and cytokine measurements are shown in figures 
3.1, 3.2, and 3.3, respectively. In figure 3.1, pulmonary resistance measured via 
FlexiVent showed no real differences between the two strains as neither achieved 
reliable increases in sensitivity to Methacholine challenge due to OVA 323-339 
sensitization and challenge. This may have been due in part to difficulties measuring 
resistance in mice caused by lesser airway smooth muscle and resulting 
bronchoconstriction, or due in part to the use of the OVA peptide instead of whole OVA, 
or perhaps a combination of these factors. In figure 3.2, a clear increase in inflammation 
in H&E-stained lung sections can be seen for OVA 323-339 sensitized and challenged 
BALB/c mice versus C57BL/6 mice. As BALB/c mice have been shown to have a 
greater propensity for developing inflammation in asthma models, this increase in 
inflammation was not unexpected. In figure 3.3, IL-13 and IL-5 were measured for each 
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strain. IL-4 was assayed as well, though amounts present were unmeasurable (data not 
shown). While IL-13 measurements did not show differences between PBS- and OVA 
323-339-treated mice, IL-5 measurements showed consistent increases in OVA 323-
339-treated mice for both strains. Due to the increased inflammation present in H&E 
sections along with the differential cell count eosinophilia for BALB/c mice however, it 
was determined that BALB/c mice would be the preferred strain to use in the model. 
Based on various protocols attempted for the generation of a pulmonary allergic 
model, it was concluded that for sensitization and challenge with the OVA peptide, 
higher levels of inflammation could be achieved in an acute model with BALB/c mice 
given subcutaneous injections of IFA and peptide for sensitizations, and at given least 
60 μL of peptide (to allow for better dispersion in the lungs) via pharyngeal aspiration for 
challenges. The design of the animal model (table 3.2) that generated sufficient 
inflammation for study (denoted by eosinophil and neutrophil differential cell counts from 
bronchoalveolar lavage fluid, figure 3.4) was in BALB/c mice, and began with OVA 323-
339 in IFA sensitizations on days 0, 7, and 14 via subcutaneous injection followed by 
challenge with a 1% OVA 323-339 solution on days 21, 22, and 23 via pharyngeal 
aspiration, then harvest on day 26. Unlike for BALB/c mice, differential cell count data 
for C57BL/6 mice did not show significant eosinophilic inflammation (data not shown). 
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Tables and Figures 
Table 3.1. Attempted models of allergen-induced airway inflammation 
Some of the protocols explored during model development are outlined. Various models 
attempted for induction of pulmonary inflammation included the use of different animal 
strains, sensitization routes, acute and chronic timelines, different adjuvants, as well as 
varying OVA 323-339 doses and numbers of sensitizations and challenges.  
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*BALB/c and C57BL/6 mice strains used 
**BALB/c mice only 
Attempted Protocols for Allergen-induced Airway Inflammation 
   
Chronic* vs Acute* 
 
Sensitization: Pharyngeal aspiration of 100 
μg OVA 323-339 + 0.1 μg LPS/75 μL (days 0 
and 6) 
 
  
Sensitization: Intraperitoneal injection of 10 
μg OVA 323-339 in 200 μL alum (days 0 
and 12) 
 
Challenge: Nose-only aerosol exposure with 
2% OVA for 30 minutes (days 13-15, 41-43, 
and 69-71) 
 
Harvest: One-third of mice on day 16, one-
third of mice on day 44, and one-third of mice 
on day 72 
 Challenge: Pharyngeal aspiration of 600 
μg OVA 323-339 in 50 μL saline (day 19) 
 
 
Harvest: Day 21 
   
IFA Adjuvant** vs Alum Adjuvant* 
 
Sensitization: Subcutaneous injection of 200 
μg OVA 323-339 in 200 μL IFA (days 0, 7, 
and 14) 
 
  
Sensitization: Intraperitoneal injection of 
200 μg OVA 323-339 in 200 μL alum (days 
0, 7, and 14) 
Challenge: Pharyngeal aspiration of 1% OVA 
323-339 in 60 μL saline (days 21-23) 
 
Harvest: Day 26 
 Challenge: Pharyngeal aspiration of 1% 
OVA 323-339 in 60 μL saline (days 21-23) 
 
Harvest: Day 26 
   
Aerosol Challenge* vs Pharyngeal Aspiration Challenge* 
 
Sensitization: Intraperitoneal injection of 10 
μg OVA 323-339 in 200 μL alum (days 0 and 
12) 
 
  
Sensitization: Subcutaneous injection of 
200 μg OVA 323-339 in 200 μL IFA (days 
0, 7, and 14) 
 
Challenge: Nose-only aerosol exposure with 
5% OVA for 30 minutes (days 18-23, 26-28, 
33-35, 40-42, 47-49, and 54-56 
 
Harvest: One-third of mice on day 29, one-
third of mice on day 36, and one-third of mice 
on day 57 
 Challenge: Pharyngeal aspiration of 1% 
OVA 323-339 in 60 μL saline (days 21-23) 
 
 
Harvest: Day 26 
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 Table 3.2. Allergen-induced airway inflammation model timeline 
In the animal model ultimately chosen for study, animals were sensitized with OVA 323-
339 in IFA on days 0, 7, and 14 via subcutaneous injection, then challenged with a 1% 
OVA 323-339 solution on days 21, 22, and 23 via pharyngeal aspiration. Animals were 
harvested on day 26. 
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 Protocol for Allergen-induced Airway Inflammation 
Day 0 Sensitization #1 
  
Day 7 Sensitization #2 
  
Day 14 Sensitization #3 
  
Day 21 Challenge #1 
  
Day 22 Challenge #2 
  
Day 23 Challenge #3 
  
Day 26 Time-point 
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Figure 3.1. Comparison of Resistance (R) percent change from baseline in PBS- 
vs. OVA-challenged C57BL/6 and BALB/c mice 
C57BL/6 (A) and BALB/c (B) mice (n = 4 per group, one experiment) were anesthetized 
with isoflurane and sensitized with either 75 μL phosphate buffered saline (PBS) or 
ovalbumin (OVA) + lipopolysaccharide (LPS) (100 μg OVA + 0.1 μg LPS/75 μL) via 
oropharyngeal aspiration on days 0 and 6. Starting on day 13 mice were be exposed to 
a nose-only aerosol of either PBS or 2% OVA (no LPS) for 30 minutes for 3 consecutive 
days. Three days of aerosol exposures were given at one-month intervals for three 
months. Three days after the final exposure, animals were subjected to increasing 
doses of methacholine (MCh) to determine changes in airway resistance (R) from 
baseline as measured via FlexiVent. Error bars represent the standard error of the 
mean for each group value. 
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Figure 3.2. Comparison of cellular infiltration in lung tissue in PBS- vs. OVA-
challenged C57BL/6 and BALB/c mice 
C57BL/6 and BALB/c mice (n = 4 per group, one experiment) were anesthetized with 
isoflurane and sensitized with either 75 μL phosphate buffered saline (PBS) or 
ovalbumin (OVA) + lipopolysaccharide (LPS) (100 μg OVA + 0.1 μg LPS/75 μL) via 
oropharyngeal aspiration on days 0 and 6. Starting on day 13 mice were be exposed to 
a nose-only aerosol of either PBS or 2% OVA (no LPS) for 30 minutes for 3 consecutive 
days. Three days of aerosol exposures were given at one-month intervals for three 
months. H&E-stained lung sections are shown at 2.5x, 10x, and 40x for each animal, 
respectively. Red arrows denote areas of inflammatory cell infiltration. 
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Figure 3.3. Comparison of serum IL-5 and IL-13 in PBS- vs. OVA-challenged 
C57BL/6 and BALB/c mice 
Mice (n = 2-4 per group per timepoint, one experiment)a were sensitized on days 0 and 
12 with OVA 323-339 and aluminum hydroxide. Six days after the second sensitization, 
mice underwent six consecutive days of aerosol challenge (5% whole OVA in PBS or 
PBS alone) on days 18-23 followed by two days of rest, then three added consecutive 
days (days 26-28) of aerosol challenge. One-third of the mice were sacrificed 24 hours 
after the day 28 aerosol challenge. Remaining mice were subjected to three 
consecutive days of aerosol challenge the following week on days 33-35, and another 
one-third of the mice were sacrificed 24 hours after the day 35 aerosol challenge. The 
last one-third of the mice were given three aerosols per week for three weeks (days 40-
42, 47-49, and 54-56), then sacrificed 24 hours after the day 56 aerosol challenge. 
Statistics were run as an unpaired t-test between mice given PBS and those given OVA 
323-339 at each timepoint. Error bars represent the standard error of the mean for each 
group value. (*) Denotes significant difference (p<0.05) versus the PBS group. 
 
a 
Some of the mice had died in the restraints during aerosol exposures, unintentionally reducing the group 
size (n) for some groups. “N” for BALB/c mice are as follows: day 29 PBS group = 2, day 29 OVA group = 
2, day 36 PBS group = 4, day 36 OVA group = 3, day 57 PBS group = 3, day 57 OVA group = 4. “N” for 
C57BL/6 mice are as follows: day 29 PBS group = 4, day 29 OVA group = 4, day 36 PBS group = 3, day 
36 OVA group = 4, day 57 PBS group = 3, day 57 OVA group = 3. 
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Figure 3.4. Neutrophil and eosinophil cell counts in PBS- vs. OVA-challenged 
BALB/c mice 
Mice were sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous 
injection, then challenged with a 1% OVA 323-339 solution on days 21, 22, and 23 via 
pharyngeal aspiration (n = 8, one experiment). Naïve mice (n = 2, one experiment) did 
not receive any treatment or manipulation. Animals were harvested on day 26. 
Eosinophils and neutrophils were counted to determine the presence of inflammation in 
BALF. Statistics were run as an unpaired t-test. Error bars represent the standard error 
of the mean for each group value. (*) Denotes significant difference (p<0.05) versus the 
Naive group. 
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Conclusion 
 In the murine model of allergen-induced airway inflammation used for the study, 
eosinophilic inflammation was observed for mice sensitized and challenged with OVA 
323-339, though eosinophilia was lower than expected compared to models that use 
whole OVA for sensitization and/or challenge. Because eosinophilic inflammation was 
measurable and consistent, however, this model should still provide insight into whether 
or not the GMCSF-OVA 323-339 fusion protein has potential as a therapeutic within the 
system. 
  
CHAPTER 4: EFFICACY OF THE GMCSF-OVA 323-339 CYTOKINE FUSION 
PROTEIN IN VIVO 
 
Introduction 
Once the animal model of allergen-induced airway inflammation using OVA 323-
339 for sensitization and challenge was established, the vehicle for testing the GMCSF-
OVA 323-339 fusion protein treatment was available to put into motion. Simply testing 
the fusion protein in vitro would not yield insight into the full potential of the fusion 
protein; it is important to observe how a treatment performs in an intact system. To test 
the GMCSF-OVA 323-339 fusion protein within the animal model used for this study, 
animals were pre-treated with GMCSF-OVA 323-339, then subjected to a model of 
pulmonary inflammation described in Chapter 3. Differences in inflammation due to 
fusion-protein treatment or lack thereof could then be measured via differential cell 
counts from BALF, lung histology, anti-OVA IgG1, and cytokine profiles for the different 
treatment groups and controls.  
For Specific Aim 3 of this study, we hypothesized that the GMCSF-OVA 323-339 
fusion protein would target the OVA peptide antigenic epitope to dendritic cell APCs, 
overloading the APCs with antigen and providing GM-CSF to encourage the 
development of a tolerogenic state. A tolerogenic state induced by cytokine antigen 
fusion protein pre-treatment could arise due to the deletion or anergization of reactive T 
cells, thereby decreasing the likelihood of T cell activation and instead, promoting 
tolerance during APC-T cell interaction. Such a state could also be induced through an 
upregulation in TRegs, leading to the suppression of reactive T cells. Tolerance to antigen 
due to GMCSF-OVA 323-339 pre-treatment would lead to a decrease in inflammatory 
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cells in differential cell counts, reduced pathology in Hematoxylin and Eosin stained lung 
sections, decreased mucus production in Alcian Blue Periodic Acid-Schiff stained lung 
sections, and decreased IgG1 and inflammatory cytokines. 
Methods 
Animals 
BALB/c mice (Jackson Labs, Bar Harbor, ME, USA), were housed at Burleson 
Research Technologies, Inc. (Morrisville, NC, USA). Animal care and use were 
performed in accordance with animal use protocols and institutional guidelines 
approved by the Burleson Research Technologies, Inc. Institutional Animal Care and 
Use Committee.  
GMCSF-OVA 323-339 (or saline) pre-treatment 
 GMCSF-OVA 323-339 fusion protein was solubilized in saline and injected 
subcutaneously into two injection sites in the hind flank (0.1 mL per injection site), for 
administration of 2 nM in 0.2 mL per mouse. Prior to injections, mice were anesthetized 
using isoflurane in a vented anesthetic chamber, and injection sites were cleaned with 
povidone-iodine followed by an alcohol rinse. Pre-treatment injections were 
administered on days -21, -14, and -7 and were monitored for signs of inflammation, 
though inflammation was unexpected. Control mice were given saline instead of 
GMCSF-OVA 323-339. 
Sensitization 
 Active sensitization of mice with OVA 323-339 in IFA was performed by 
subcutaneous injection of 200 μg OVA 323-339 in 200 μL IFA. As with fusion protein 
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pre-treatment injections, prior to sensitization injections, mice were anesthetized using 
isoflurane in a vented anesthetic chamber and injection sites were cleaned with 
povidone-iodine followed by an alcohol rinse.  Sensitizations were performed on days 0, 
7, and 14, and injection sites were monitored for signs of inflammation.  
Challenge 
 Mice were challenged via pharyngeal aspiration (p.a.) challenge on days 21, 22 
and 23. The p.a. solution was 60 μL of 1% OVA-323-339 in sterile saline, and was 
administered while mice were anesthetized with isoflurane in a vented anesthetic 
chamber. Control mice did not receive 1% OVA 323-339 solution and instead were 
given 60 μL saline. 
Serum collection 
 On day 26, mice were asphyxiated with C02 and terminal bleeds were performed 
via intracardiac puncture. Whole blood collected from terminal bleeds was placed in 
serum separator tubes and centrifuged at 1,500 x g for 10 minutes at 4˚C to obtain 
serum. Serum was collected for assay of antibody titers, and to obtain cells for in vitro 
experimentation. Serum samples were stored at -80°C until assayed. 
Bronchoalveolar lavage (BAL)  
 Shortly following euthanasia, the chest cavity was opened and the left lung was 
clamped for later removal for use in histology. Mice were then tracheostomized and 
cannulated, and BALs were performed on the right lung to obtain lavage fluid containing 
localized lung cytokines for cytokine analysis and lung cells for differential cell counts. 
BALs were performed by introducing HBSS (26 mL/kg body weight) into the right lung 
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via a 1cc syringe, then withdrawing fluid through the cannula a total of four times in 
order to collect lung cells. The first fluid withdrawal was collected separately for cytokine 
analysis, and the remaining three withdrawals were pooled for cytospins and differential 
cell counting. Primary lavage samples were stored at -80°C until assayed. 
Cytospins 
 BAL samples were centrifuged at 500 x g for 10 minutes at 4˚C. The cell pellet 
was resuspended in 0.5 mL HBSS, and cell counts performed. Volumes were adjusted 
and added for cytospin to allow for 20,000 cells per slide. The cytospin apparatus was 
run at 100 x g for 5 minutes, then slides were removed and allowed to dry. Once dry, 
slides were stained with H&E stain so that differential cell counts could be performed. 
Differential cell counts 
 Differential cell counts were performed on stained cytospin slides from BAL 
samples to provide data on the cellular profile of the lung from which the sample was 
obtained. Three hundred cells per slide were identified and counted. Common cell types 
observed and counted for each sample included monocytes, macrophages, neutrophils, 
eosinophils, lymphocytes, and epithelial cells. Statistical differences in group differential 
cell counts were determined with GraphPad Prism version 6.  
Anti-OVA IgG1 ELISA 
 An anti-OVA IgG1 ELISA was performed using the Anti-Ovalbumin IgG1 (mouse) 
EIA Kit from Cayman Chemical Company (cat# 500830). The anti-OVA IgG1 assay was 
performed on mouse serum samples according to instructions provided with kit, and the 
assay plate was read with Softmax Pro software. Statistical differences in group IgG1 
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levels were determined with GraphPad Prism version 6. 
Cytokine analysis 
 Cytokine analysis was performed on bronchoalveolar lavage samples with custom 
multiplex mouse cytokine assay kit, plate reader, and software from Meso Scale 
Discovery. Assay was performed as instructed by the kit. Lavage fluid was tested for IL-
4, IL-5, IL-10, and IFN-γ. Statistical differences in group cytokine levels were 
determined with GraphPad Prism version 6. 
Histology 
 Following BAL collection, the left lung was unclamped, inflated with 10% formalin, 
and stored in 10% formalin for 24-72 hours. Following fixation, the left lung was 
sectioned into thirds and placed in 70% ethanol for at least 24 hours. The left lung was 
then embedded in paraffin, cut into 5µm sections, mounted onto slides, and stained with 
Hematoxylin and Eosin (H&E) and Alcian Blue Periodic Acid-Schiff (AB-PAS) stains. 
H&E- and AB-PAS-stained lung sections were evaluated by Dr. Rodney Miller from EPL 
in Durham, NC (see full report and raw data in Appendix C). Sections were graded 
based on the degree of perivascular infiltration, peribronchial and peribronchiolar 
infiltration, epithelial damage, and parenchymal infiltration, and were assigned scores of 
“-”, denoting no effect, “X”, denoting no remarkable effect, “+1”, denoting minimal effect, 
“+2”, denoting slight effect, or “+3”, denoting moderate effect. No sections received 
grades higher than +3. 
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Results and Discussion 
 The key finding from this study was that GMCSF-OVA 323-339 pre-treatment in 
the pulmonary inflammatory model (table 4.1) attenuated the development of 
inflammation. Mice given saline prior to sensitization and challenge with OVA 323-339 
showed consistent, measurable, significant increases in pulmonary inflammation 
compared to mice that received GMCSF-OVA 323-339 pre-treatment prior to 
sensitization and challenge with the OVA peptide and controls that did not undergo 
challenge with the OVA peptide. Mice given saline prior to sensitization and challenge 
showed eosinophilia in cytospin slides for differential cell counts (figure 4.1), cellular 
infiltration and cuffing of the airways in H&E-stained lung sections (figure 4.2), and a 
light mucus response in the AB-PAS-stained lung sections (figure 4.3), while mice given 
GMCSF-OVA 323-339 pre-treatment showed a marked reduction in eosinophils, absent 
or only slight cellular infiltration in lung sections, and no mucus secretion. To validate 
the use of histological sections in the evaluation of the GMCSF-OVA 323-339 pre-
treatment, histological sections were sent for scoring by an outside party. The findings 
of Dr. Rodney Miller from EPL, Inc. in Durham, NC (figure 4.4; see full report and raw 
data in Appendix C) support a protective effect due to GMCSF-OVA 323-339 pre-
treatment in the model. In agreement with differential cell count data and histological 
findings, serum analysis indicated a significant elevation in IgG1, an indicator of TH2 
activity in murine models, for mice given saline prior to sensitization and challenge 
compared to those pre-treated with GMCSF-OVA 323-339 (figure 4.6). In addition, 
cytokine analysis of bronchoalveolar lavage fluid showed a significant increase in IFN-γ 
for mice given saline prior to sensitization and challenge compared to those pre-treated 
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with GMCSF-OVA 323-339 (figure 4.5). Studies have shown that IFN-γ localized in the 
lung tissue can result in increases in pro-inflammatory IL-5 and IL-13, as well as 
increased numbers of eosinophils in lavage fluid (Koch et al., 2006). While no increase 
in IL-5 was detected in the cytokine analysis, this was likely due to the timing of sample 
collection at three days post-challenge. Other studies have indicated post-challenge 
peak IL-5 concentrations at 12 hours in serum and 24 hours in bronchoalveolar lavage 
fluid, explaining the lack of IL-5 seen in this set of experiments. IL-4 was likely missed 
due to the timing of sample collection as well, with post-challenge peak concentrations 
reported at 3 hours in the serum and 24 hours in lavage fluid (Ohkawara et al., 1997). 
 Due to the successes of cytokine-antigen fusion proteins in other experimental 
systems such as Experimental Autoimmune Encephalomyelitis (EAE) with Mannie et 
al., it was thought that there would be potential for similar treatments within an animal 
model of pulmonary inflammation. While the pathogenesis of each disorder is quite 
different, each begins with the immune system engaging in an inappropriate response 
to typically innocuous antigen. Therefore, the underlying idea of targeting antigen to 
specific antigen presenting cell populations in an effort to tolerize the immune system in 
each disorder is quite similar. It was unsure, however, how GM-CSF would perform as 
the cytokine chosen for linkage to antigen within a model of pulmonary inflammation. 
While GMCSF linked to antigen, for example, has been used in EAE experiments by 
Mannie et al., EAE is rooted in TH1-dominated responses while asthma is typically TH2 
in nature, and it was uncertain whether or not the same cytokine domain would behave 
similarly in oppositely polarized systems. This data suggests that despite the differences 
in TH polarity related to immunopathology for murine EAE and pulmonary inflammation 
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models, GM-CSF performs well as the cytokine domain portion of therapeutic fusion 
proteins. 
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Tables and Figures 
Table 4.1. Allergen-induced airway Inflammation model with GMCSF-OVA 323-339 
pre-treatment 
Animals were pre-treated with either GMCSF-OVA 323-339 or saline on days -21, -14, 
and -7 via subcutaneous injection. Animals were then sensitized with OVA 323-339 in 
IFA on days 0, 7, and 14 via subcutaneous injection, and challenged with either a 1% 
OVA 323-339 solution or saline on days 21, 22, and 23 via pharyngeal aspiration. 
Animals were euthanized on day 26. 
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 Pre-Treatment Protocol 
Pre-treatment with GMCSF-OVA 323-339 Pre-treatment with saline 
Saline Group* OVA323-339 Group* Saline Group* OVA 323-339 Group* 
    
Day -21 Pre-treatment #1 Pre-treatment #1 
     
Day -14 Pre-treatment #2 Pre-treatment #2 
     
Day -7 Pre-treatment #3 Pre-treatment #3 
     
Day 0 Sensitization #1 Sensitization #1 
     
Day 7 Sensitization #2 Sensitization #2 
     
Day 14 Sensitization #3 Sensitization #3 
     
Day 21 Challenge #1 Challenge #1 
     
Day 22 Challenge #2 Challenge #2 
     
Day 23 Challenge #3 Challenge #3 
     
Day 26 Time-point Time-point 
*n = 10 per group 
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Figure 4.1. Differential cell counts in saline- vs. GMCSF-OVA 323-339- pretreated 
BALB/c mice 
Mice were pre-treated with either saline or GMCSF-OVA 323-339 on days -21, -14, and 
-7; sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection; 
and challenged with either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 
via pharyngeal aspiration (n=10 per group for each of four groups, one experiment). 
Animals were harvested on day 26. Eosinophils and neutrophils were counted along 
with macrophages, monocytes, lymphocytes, and epithelial cells to determine the 
presence of inflammation in BALF. Statistics were run as a one-way ANOVA with 
Dunnett’s multiple comparisons test and a single pooled variance. (*) Denotes 
significant difference (p<0.05) versus the GMCSF-OVA pre-treated, sensitized and 
challenged group. Error bars represent the standard error of the mean for each group 
value. 
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Figure 4.2. H&E-stained lung sections for saline- vs. GMCSF-OVA 323-339- 
pretreated BALB/c mice 
Mice were pre-treated with either saline or GMCSF-OVA 323-339 on days -21, -14, and 
-7; sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection; 
and challenged with either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 
via pharyngeal aspiration (n=10 per group for each of four groups, one experiment). 
Animals were harvested on day 26. Lung sections from the left lung of each mouse 
were stained with H&E to visualize perivascular infiltration, peribronchial and 
peribronchiolar infiltration, epithelial damage, and parenchymal infiltration (or lack 
thereof). Red arrows in G-H denote areas of inflammatory cell infiltration. 
 
A-B: Negative control mice given GMCSF-OVA 323-339 pre-treatment followed by sensitization only. 
C-D: Mice given GMCSF-OVA 323-339 pretreatment followed by sensitization and challenge. 
E-F: Negative control mice given saline pre-treatment followed by sensitization only. 
G-H: Positive control mice given saline pretreatment followed by sensitization and challenge. 
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Figure 4.3. Alcian Blue Periodic Acid-Schiff-stained lung sections for saline- vs. 
GMCSF-OVA 323-339- pretreated BALB/c mice 
Mice were pre-treated with either saline or GMCSF-OVA 323-339 on days -21, -14, and 
-7; sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection; 
and challenged with either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 
via pharyngeal aspiration (n=10 per group for each of four groups, one experiment). 
Animals were harvested on day 26. Lung sections from the left lung of each mouse 
were stained with Alcian Blue Periodic Acid-Schiff to visualize mucus production (or lack 
thereof). Mucus present in the sections stained deep purple and blue hues. Red arrows 
in G-H denote areas of mucus staining. 
 
A-B: Negative control mice given GMCSF-OVA 323-339 pre-treatment followed by sensitization only. 
C-D: Mice given GMCSF-OVA 323-339 pretreatment followed by sensitization and challenge. 
E-F: Negative control mice given saline pre-treatment followed by sensitization only. 
G-H: Positive control mice given saline pretreatment followed by sensitization and challenge. 
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Figure 4.4. Scoring of histological sections 
H&E- and Alcian Blue Periodic Acid-Schiff-stained lung sections were evaluated by Dr. 
Rodney Miller from EPL, Inc. in Durham, NC (see full report and raw data in Appendix 
C). Sections were graded based on the degree of perivascular infiltration, peribronchial 
and peribronchiolar infiltration, epithelial damage, parenchymal infiltration, and large 
and small airway mucus deposition. For each characteristic, sections were assigned 
scores of “-”, denoting no effect, “X”, denoting no remarkable effect, “+1”, denoting 
minimal effect, “+2”, denoting slight effect, or “+3”, denoting moderate effect. No 
sections received grades higher than +3. 
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GMCSF-OVA 
323-339 pre-
treatment 
followed by 
sensitization, 
no challenge 
901 X X X X +1 - 1 
0.5 
902 X X X X - - 0 
903 X X X X +1 - 1 
904 X X X X - - 0 
905 X X X X +1 - 1 
906 X X X X - - 0 
907 X X X X - - 0 
908 X X X X +1 - 1 
909 X X X X - - 0 
910 X X X X +1 - 1 
GMCSF-OVA 
323-339 pre-
treatment 
followed by 
sensitization 
and 
challenge 
911 X X X X +1 - 1 
1.2 
912 X X X X +1 - 1 
913 X X X X +1 - 1 
914 X X X +1 +1 - 2 
915 X X X X +1 - 1 
916 X X X X +1 - 1 
917 X X X X +1 - 1 
918 X X X X +2 - 2 
919 X X X X +1 - 1 
920 X X X X +1 - 1 
Saline pre-
treatment 
followed by 
sensitization, 
no challenge 
921 X X X X +1 - 1 
1.5 
922 X X X X +1 - 1 
923 X X X X +1 - 1 
924 X X X X +1 - 1 
925 +2 +2 X +1 +1 - 6 
926 X X X X +1 - 1 
927 X X X X - - 0 
928 X +1 X +1 - - 2 
929 X X X X +1 - 1 
930 X X X X +1 - 1 
Saline pre-
treatment 
followed by 
sensitization 
and 
challenge 
931 X +1 X X +1 - 2 
7.2 
932 +2 +2 X X +2 - 6 
933 +3 +3 X +2 +3 +1 12 
934 +2 +2 X +1 +2 +1 8 
935 +1 +1 X X +1 - 3 
936 +3 +3 X +1 +2 - 9 
937 +3 +3 X +1 +2 - 9 
938 +2 +2 X +1 +1 - 6 
939 +3 +3 X +2 +3 +1 12 
940 +2 +2 X X +1 - 5 
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Figure 4.5. IL-4, IL-5, IL-10, and IFN-γ comparison for saline- vs. GMCSF-OVA 323-
339- pretreated BALB/c mice 
Mice were pre-treated with either saline or GMCSF-OVA 323-339 on days -21, -14, and 
-7; sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection; 
and challenged with either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 
via pharyngeal aspiration (n=10 per group for each of four groups, one experiment). 
Animals were harvested on day 26, at which time, bronchoalveolar lavage samples 
were obtained. Lavage fluid was then tested for IL-4, IL-5, IL-10, and IFN-γ. Statistics 
were run as a one-way ANOVA with Dunnett’s multiple comparisons test and a single 
pooled variance. (*) Denotes significant difference (p<0.05) versus the GMCSF-OVA 
323-339 pre-treated, sensitized and challenged group. Error bars represent the 
standard error of the mean for each group value. 
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Figure 4.6. Serum IgG1 comparison for saline- vs. GMCSF-OVA 323-339- 
pretreated BALB/c mice 
Mice were pre-treated with either saline or GMCSF-OVA 323-339 on days -21, -14, and 
-7; sensitized with OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection; 
and challenged with either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 
via pharyngeal aspiration (n=10 per group for each of four groups, one experiment). 
Animals were harvested on day 26, at which time, terminal blood collections were 
obtained. Serum was then tested for OVA-specific IgG1. Statistics were run as a one-
way ANOVA with Dunnett’s multiple comparisons test and a single pooled variance. (*) 
Denotes significant difference (p<0.05) versus the Saline pre-treated, sensitized and 
challenged group. Error bars represent the standard error of the mean for each group 
value. 
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Conclusion 
The GMCSF-OVA 323-339 fusion protein attenuated much of the pulmonary 
inflammation associated with the model used in this study. When OT-II.2 T cell 
responses to the fusion protein were analyzed via flow cytometry, however, data did not 
suggest an effect on CD3, CD4, TCRVβ5, or TCRVα2 populations, perhaps indicating a 
role for immunosuppressive TReg mechanisms unrelated to apoptosis of effector cells. 
The data shown suggests that fusion proteins such as GMCSF-OVA 323-339 have 
potential as immunomodulators within a model of pulmonary inflammation. Further 
study to determine dose, timing of treatment, and other cytokine-antigen fusion protein 
combinations within the model are warranted.  
  
CHAPTER 5: GENERAL DISCUSSION 
 
Study Summary 
Allergic asthma is a significant medical problem, affecting more than 300 million 
individuals and causing approximately 250,000 deaths every year (Global surveillance, 
prevention and control of chronic respiratory diseases: A comprehensive approach. 
2007; Heron et al., 2009). Current asthma therapies temporarily minimize discomfort 
and manage symptoms, but there are no effective long-term, preventative, or curative 
agents available. Complexities in development and regulation of immune processes, as 
well as complexities in the interaction of the immune system with cellular and molecular 
pathways controlling development and function of the pulmonary system, have thwarted 
development of novel efficacious therapeutics. To date, the management of asthma 
symptoms has largely been through the use of bronchodilators and inhaled steroids and 
corticosteroids. The prescription of leukotriene inhibitors and anti-IgE therapies has also 
aided in management of symptoms. Bronchodilators may be short- or long-acting, and 
are typically β2 agonists (short-acting), anti-cholinergics (paired with short- or long-
acting agents), and/or theophylline (long-acting) (Spencer and Krieger, 2013). Short-
acting bronchodilators can be used to reverse symptoms once they have appeared or 
as an emergency measure, but do not manage the underlying inflammation. Long-
acting bronchodilators do not provide immediate relief, but are typically used together 
with inhaled steroids for added prevention of acute attacks. Inhaled steroids and 
corticosteroids are used to lessen airway inflammation in an effort to reduce the 
chances of the onset of an acute asthma attack. They must be taken at least once daily 
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or as prescribed to help control inflammation, but are not useful once symptoms are 
present. Leukotriene inhibitors have been used due to their anti-inflammatory effects, 
but are not as effective as corticosteroids and are therefore used for mild or moderate 
asthma cases or in conjunction with corticosteroids. Anti-IgE therapy has been 
prescribed to patients with severe and persistent asthma, although anaphylaxis is a 
potential side effect of the treatment (Spencer and Krieger, 2013). 
Definition of phenotype-specific pathogenic factors has shown some promise in 
establishing effectiveness of agents targeting the IL-4 and IL-13 pathways. Elucidation 
of the role of innate immunity in asthma is leading to better understanding of how lipids 
and viruses can induce exacerbations in allergic asthmatics, even when their allergies 
are otherwise well controlled. However, other than some encouraging results from 
animal studies with agents that interrupt inflammation induced via the OX40 pathway 
(Kaur and Brightling, 2012), and modest effects of Pitrakinra (recombinant protein 
targeting IL-4Rα, attenuating IL-4 and IL-13 signaling) (Antoniu, 2010b), MEDI-528 
(anti-IL-9 antibody) (Antoniu, 2010a; Parker et al., 2011), and Mepolizumab (anti-IL-5 
antibody) (Busse et al., 2010; Nair et al., 2009; Haldar et al., 2009; Wenzel, 2009), little 
has emerged in terms of translating the basic observations into effective and affordable 
treatments. It is important, therefore, to continue investigations into new, novel 
therapeutics.  
Recent studies have indicated that targeting immunogens to specific immune 
cells via fusion with cytokines increases the effectiveness of immunotherapy in animal 
models for asthma as well as other immune-mediated disease models such as 
experimental autoimmune encephalitis (Mannie et al., 2007b; Blanchfield and Mannie, 
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2010; Kim et al., 1997; Maecker et al., 2001; Maecker et al., 2001; Mannie and Abbott, 
2007; Mannie et al., 2007a). These cytokine-antigen fusion proteins target antigen to 
specific antigen presenting cell populations (Mannie et al., 2007b; Blanchfield and 
Mannie, 2010), upregulate T Regulatory cells (Mannie et al., 2007b), bias the immune 
system toward TH1 responses (Kim et al., 1997; Maecker et al., 2001), and induce 
immunological tolerance to antigen (Mannie et al., 2007b; Blanchfield and Mannie, 
2010). Cytokines involved in asthma pathogenesis include the TH2-specific cytokines - 
IL-4, IL-5, and IL-13 - as well as general cytokine growth factors such as IL-2, a growth 
factor for lymphocytes, and GM-CSF, a growth factor for neutrophils, eosinophils, and 
basophils (Mannie et al., 2007b; Blanchfield and Mannie, 2010). Upon exposure of DC 
and macrophage APC cytokine receptors to specific signals such GM-CSF, APC are 
more inclined to develop a tolerogenic state, leading to the deletion or anergization of 
reactive T cells (Kapsenberg, 2003) or the induction of suppressive TRegs (Ganesh et al., 
2009; Dhodapkar et al., 2001). As many murine asthma models use ovalbumin to 
induce allergic inflammation, OVA 323-339, the primary antigenic domain of ovalbumin, 
could thus be targeted to DC and macrophage APC populations in an effort to tolerize 
the immune system and reverse asthma symptoms.  
The objective of this study was to test the hypothesis that fusion proteins 
comprised of GM-CSF and OVA 323-339 epitopes potentiate antigen-specific 
immunological tolerance and attenuate development of asthma. The objective was 
achieved through three Specific Aims: 1) the establishment of the efficacy of the 
GMCSF-OVA 323-339 cytokine-fusion protein in vitro, 2) the development of a murine 
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asthma model for testing of the cytokine-fusion protein, and 3) the verification of the 
efficacy of GMCSF-OVA 323-339 cytokine-fusion proteins in vivo. 
In Specific Aim 1, to establish of the efficacy of the GMCSF-OVA 323-339 
cytokine-fusion protein in vitro, GMCSF-OVA 323-339 cytokine fusion construct DNA 
was generated via PCR, transformed into Top10 E. Coli, expanded, and purified. DNA 
constructs were transfected into 293F Human Embryonic Kidney (HEK) cells, a stable 
line was generated, and protein secreted in supernatant was collected, pooled, 
concentrated, and purified. The bioactivity of cytokine and antigenic domains was 
confirmed individually with [3H]thymidine incorporation bioassays. GMCSF-OVA 323-
339 cultured with cells from the Memory OT-II.2 T Cell Line caused antigenic domain 
bioactivity to be left-shifted compared with the OVA 323-339 positive control, suggesting 
targeting of antigen to T Cell responders. The cytokine domain of GMCSF-OVA 323-
339 purified protein was shown to have biological activity similar to that of the GM-CSF 
positive control. Taken together with the antigenic domain bioactivity data, the GMCSF-
OVA 323-339 was considered to be a fully functional protein with neither domain 
affected by fusion to the other. 
In Specific Aim 2, in order to develop a murine model of allergen-induced airway 
inflammation for testing of the cytokine-fusion protein, many different protocols and 
avenues were pursued. This was made necessary by the fact that very few models use 
OVA 323-339 for both sensitization and challenge, and to that effect, many of the 
models attempted did not yield a robust inflammatory response. Options explored 
during model development included chronic vs. acute models, the use of a C57BL/6 vs. 
BALB/c mouse strains, the use of various adjuvants, sensitization routes, and challenge 
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routes, as well as varying OVA 323-339 doses, and numbers of sensitizations and 
challenges; the success or failure of each protocol was evaluated based on its ability to 
produce pulmonary inflammation, particularly eosinophilic inflammation. Based on the 
various protocols attempted for the generation of a pulmonary allergic model, it was 
decided that for sensitization and challenge with the OVA peptide, higher levels of 
inflammation could be achieved in an acute model with BALB/c mice given 
subcutaneous injections of IFA and peptide for sensitizations, and given at least 60 μL 
of peptide (to allow for better dispersion in the lungs) via pharyngeal aspiration for 
challenges. The animal model ultimately chosen for the study was as follows: 
sensitization with 200 μg OVA 323-339 in 200 μL IFA on days 0, 7, and 14 via 
subcutaneous injection; challenge with 60 μL of either a 1% OVA 323-339 solution or 
saline on days 21, 22, and 23 via pharyngeal aspiration; and harvest on day 26. 
Although pulmonary inflammation did not reach levels comparable to that of models with 
whole OVA for sensitization and/or challenge, inflammation was primarily eosinophilic, 
measurable, and consistent. Due to the measurable, consistent effects, it was decided 
that this model would be appropriate to determine whether or not GMCSF-OVA 323-339 
exhibits immunomodulatory potential within a defined system. 
In Specific Aim 3, to verify the efficacy of the GMCSF-OVA 323-339 cytokine-
fusion protein in vivo, mice were pre-treated with either GMCSF-OVA 323-339 or saline 
on days -21, -14, and -7 via subcutaneous injection. Animals were then sensitized with 
OVA 323-339 in IFA on days 0, 7, and 14 via subcutaneous injection, challenged with 
either a 1% OVA 323-339 solution or saline on days 21, 22, and 23 via pharyngeal 
aspiration, and harvested on day 26. Pre-treatment of mice with GMCSF-OVA 323-339 
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fusion proteins reduced pulmonary inflammation within the model compared to that of 
mice given saline treatment. The numbers of eosinophils present in the BAL fluid of 
mice, as determined by differential cell counts, were significantly fewer for mice that 
received the fusion protein prior to sensitization and challenge with OVA 323-339. 
Histological scoring of H&E- and AB-PAS-stained sections agreed with the differential 
cell count data, showing pulmonary cellular infiltration and cuffing of the airways, along 
with a mild mucus response, in stained lung sections for animals treated with saline 
versus little-to-no cellular infiltration or mucus production for mice treated with fusion 
protein. Supporting the differential cell count data and histological findings, serum 
analysis indicated a significant increase in IgG1, an indicator of TH2 activity in murine 
models, for mice given saline compared to those pre-treated with GMCSF-OVA 323-339 
prior to sensitization and challenge. In addition, cytokine analysis of bronchoalveolar 
lavage fluid showed a significant increase in IFN-γ for mice given saline prior to 
sensitization and challenge compared to those pre-treated with GMCSF-OVA 323-339. 
In a study by Koch et al., it was shown that IFN-γ localized in the lung tissue can result 
in increased IL-5 and IL-13, as well as elevated eosinophils numbers in lavage fluid 
(Koch et al., 2006).  
Overall, the observed reduction in pulmonary inflammation and mucus 
demonstrates that GMCSF-OVA 323-339 fusion proteins have the capability of 
influencing immune responses within a murine model of allergen-induced airway 
inflammation, and suggests that cytokine-fusion therapies may have potential as 
asthma therapeutics. Yet, there were uncertainties regarding how GM-CSF would 
perform as the cytokine chosen for fusion within a model of pulmonary inflammation, 
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given that GM-CSF has been shown to exert both anti-inflammatory as well as pro-
inflammatory effects under different circumstances. The importance of GM-CSF in 
macrophage function is illustrated in GM-CSF knockout mice, which develop alveolar 
proteinosis, a state characterized by impaired macrophage function, an accumulation of 
surfactant in the airways, and inefficient gas exchange (Hamilton and Anderson, 2004). 
Alveolar proteinosis can also develop due to defects in the β chain of the GM-CSF 
receptor, causing interference with GM-CSF signaling (Hamilton, 2002). GM-CSF 
overexpression in human populations, caused by certain malignancies such as myeloid 
leukemia, results in the differentiation of cancerous cells as well as the generation of 
GM-CSF-neutralizing auto-antibody and subsequent alveolar proteinosis (Shi et al., 
2006; Hamilton, 2002). Neutropenia caused by cancer or resulting chemotherapy 
treatment may be treated with GM-CSF or with recombinant GM-CSF therapies such as 
Sargramostim (Leukine) to mobilize stem cells. Bone marrow transplant recipients may 
also receive GM-CSF therapy to aid in myeloid reconstitution. Patients receiving GM-
CSF therapy that have also been diagnosed with rheumatoid arthritis, however, 
experience a worsening of arthritis symptoms as a side-effect, indicating a pro-
inflammatory role for GM-CSF (Shi et al., 2006). 
Further supporting a pro-inflammatory role for GM-CSF, GM-CSF has been 
observed to contribute to TH17-induced inflammatory responses, and transgenics 
expressing GM-CSF in the stomach have been shown to develop autoimmune gastritis 
(Shi et al., 2006; McGeachy, 2011). In studies with GM-CSF knockout mice, mice are 
resistant to development of EAE and type I diabetes in the respective disease models 
(Hamilton, 2002; Enzler et al., 2007). In asthma models, treatment with anti-GM-CSF 
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antibody attenuates sensitization to aeroallergens, allergen-induced inflammation, and 
AHR (Hamilton and Anderson, 2004). Consistent with the mucosal sources of GM-CSF, 
GM-CSF mRNA is increased in the airways of human asthmatics (Chung and Barnes, 
1999) where it promotes maturation, activation, and growth of monocytes and DCs 
resulting in increased antigen presentation and activation of antigen-specific B and T 
cells (Blanchfield and Mannie, 2010; Ganesh et al., 2009; Hamilton and Anderson, 
2004; Ritz et al., 2002). Clinical application of GM-CSF inhibition has been seen with 
Mavrilmumab, a rheumatoid arthritis treatment targeting GM-CSFRα, and with MOR 
103, an anti-GMCSF treatment used in multiple sclerosis (Nair et al., 2012; Deiß et al., 
2013). 
GM-CSF has also been shown to exert anti-inflammatory roles, however. GM-
CSF treatment in rodent models of experimental autoimmune myasthenia gravis 
inhibited disease progression through the induction of immunosuppressive TRegs, and 
likewise inhibited experimental autoimmune thyroiditis and type 1 diabetes in rodent 
models through dendritic cell interaction and TReg induction (Cheatem et al., 2009; 
Ganesh et al., 2009; Sheng et al., 2006). Clinical application of GM-CSF has been 
observed with Sipleucel-T (Provenge), an FDA-approved cancer vaccine. In this 
treatment, a patient’s peripheral blood mononuclear cells (including dendritic cell APC) 
are collected and incubated with GMCSF-PAP, a fusion protein comprised of GM-CSF 
and PAP (prostatic acid phosphatase), a protein found on the majority of prostate 
cancer cells. The cultured cells are then re-introduced into the patient, altering tumor 
antigen presentation and aiding in the tumor immune response (Shore et al., 2013). 
GMCSF linked to antigen in EAE experiments by Mannie et al., has also resulted in an 
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altered immune response leading to attenuation of symptoms. Due to the opposing 
effects seen for GM-CSF in the rodent type 1 diabetes model, as well as opposing pro- 
and anti-inflammatory effects observed in other models and therapies, it is likely that the 
timing of GM-CSF administration or the balance of GM-CSF determines the nature of its 
effect.  
Due to the successes of cytokine-antigen fusion proteins in other experimental 
systems such as Experimental Autoimmune Encephalomyelitis (EAE) with Mannie et 
al., it is not surprising to have found similar potential for related cytokine-antigen fusion 
treatments within an animal model of airway inflammation. Despite a differing 
pathogenesis in each disorder, each shares a commonality: that the immune system 
engages in an inappropriate response to innocuous antigen. Therefore, the underlying 
concept of targeting antigen to specific antigen presenting cell populations in an effort to 
tolerize the immune system in each disorder is quite similar. Antigenic targeting is 
achieved by increasing antigen concentration and subsequent uptake and presentation 
on the surface of dendritic cells via linkage of the GM-CSF domain of the fusion protein 
to GM-CSF receptors on the surface of dendritic cells. Tolerance to the antigen may 
then develop due to the effects of GM-CSF on dendritic cells or due to an upregulation 
in immunosuppressive TRegs acting through a variety of mechanisms, including the 
release of granzymes causing effector T cell apoptosis, the release of anti-inflammatory 
cytokines such as IL-10 and TGF-β, sequestration of IL-2 leading to T effector cell death 
due to cytokine deprivation, cell-contact mediated mechanisms leading to T effector cell 
cycle arrest or APC immaturity, as well as through competing for T effector cell growth 
factors such as IL-2 (Vock et al., 2010). Indeed, in experiments by Ganesh et al., GM-
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SCF-treated DCs adopted a semi-mature phenotype, and the GM-CSF-treated DCs 
induced TReg expansion and attenuation of autoimmune thyroiditis in a murine model 
(Ganesh et al., 2009). In other experiments by Gaudreau et al., mice treated with GM-
CSF showed increased numbers of immature and semi-mature DCs, and that these 
DCs were critical in maintaining the immunosuppressive effects of TRegs in a model of 
autoimmune diabetes (Gaudreau et al., 2007). Furthermore, studies by Kared et al. 
showed that GM-CSF interacted with TRegs through the GM-CSF receptor α-chain 
CD116, and that this interaction increased TReg suppressive potency (Kared et al., 
2008). (Cheatem et al., 2009; Ganesh et al., 2009; Sheng et al., 2006). In addition, 
clinical application of GM-CSF has been observed with Sipleucel-T (Provenge), an 
FDA-approved cancer vaccine in which a patient’s peripheral blood mononuclear cells 
(including dendritic cell APC) are collected and incubated with GMCSF-PAP, a fusion 
protein comprised of GM-CSF and PAP (prostatic acid phosphatase), a protein common 
to prostate cancer cells. Following incubation, cells are re-introduced into the patient, 
aiding in the tumor immune response via altered tumor antigen presentation (Shore et 
al., 2013). GMCSF-OVA 323-339 fusion proteins, then, may target antigen to DC APC 
and induce an immature or semi-mature phenotype, leading to less effective antigen 
presentation and support for TReg activity. This data suggests that despite its potential to 
increase inflammation, GM-CSF performs well as the cytokine domain portion of 
therapeutic fusion proteins. 
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Future Directions and Study Alternatives 
Animal Models 
 It was recognized from the start of the study that the mouse model of allergen-
induced airway inflammation would need to show consistent and significant differences 
between OVA 323-339- and PBS-challenged animal groups, because if not, it would be 
ill-suited to demonstrating vaccine efficacy. While chronic models are understood to be 
a relevant model system as they more closely mimic some of the human asthma 
symptoms, it proved difficult to obtain reliable results with this model system in 
experiments in this project. Even acute mouse models, although well-characterized and 
often used in the literature, were problematic in that they did not induce high levels of 
eosinophilic inflammation in our system. While the acute model protocol utilized for this 
study was consistent and significant, it was weaker than many of the other pulmonary 
inflammation models used in the literature. Perhaps this was due to the fact that most 
ovalbumin-based models use whole ovalbumin for sensitization and challenge, and the 
17-amino acid OVA 323-339 was not antigenic enough to illicit a robust inflammatory 
response when used for both sensitization and challenge. An alternative approach that 
could be pursued would be that of an adoptive transfer-induced mouse model of 
pulmonary inflammation. In an adoptive transfer model, T cells could be harvested from 
DO11.10 mice (BALB/c transgenic mice with an OVA 323-339-responsive T cell 
repertoire), then cultured with OVA 323-339. Cultured cells could then be adoptively 
transferred into wild-type BALB/c mice. Finally, mice would undergo a challenge with 
OVA 323-339, which might drive a more potent eosinophilic inflammation than we have 
observed in this study. While a stronger, more potent inflammatory model would be 
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potentially more difficult for fusion protein treatments to overcome, it could provide 
added information on the potency of fusion protein treatments. 
Dose and Pharmacokinetic Analysis of the GMCSF-OVA 323-339 Fusion Protein 
 The GMCSF-OVA 323-339 fusion protein used in this study was not subjected to 
pharmacokinetic analysis. Pharmacokinetic analysis of the fusion protein could provide 
valuable insight into treatment efficacy through examining the relationship between the 
treatment concentrations administered to study animals, the time required for the 
bioavailability of given treatment concentrations to diminish, and the time required for 
the production of biomarkers indicating treatment effect. Because fusion proteins are 
expected to be targeted to dendritic cell and macrophage APC populations, systemic 
bioavailability would be expected to increase initially, and then decrease as the 
treatment reached its targets. As systemic bioavailability decreased, biomarkers 
indicating fusion protein activity would then be expected to increase.  
Since cytokine domain and antigenic domain bioassays have been developed to 
test GMCSF-OVA 323-339 bioactivity (described previously), and since these bioassays 
could also be used to test for GMCSF-OVA 323-339 systemic bioavailability in the 
serum, the next step in the process would be to determine appropriate biomarkers for 
fusion protein activity. Biomarkers could be selected with a set of in vitro assays 
combining mouse splenocytes containing dendritic cells and macrophages with 
GMCSF-OVA 323-339, and detecting increases in various cytokines via ELISA or 
Multiplex assay. Any cytokines significantly increased by the interaction of GMCSF-OVA 
323-339 with mouse APC in vitro could potentially be used as biomarkers of fusion 
protein activity in vivo. The pharmacokinetic analysis would be conducted by 
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administering various doses of treatment, then sampling serum from animals at regular 
time-points post-administration to test for the presence of GMCSF-OVA 323-339 
bioactivity as well as the presence of biomarkers indicative of GMCSF-OVA 323-339 
efficacy. The results of the analysis could provide information used to optimize dose 
concentration and timing with respect to the induction of the asthma model. It would 
also be interesting to explore the use of the cytokine-fusion protein as a treatment (after 
the sensitization and/or challenge within the asthma model) instead of as a pre-
treatment (as was done in this study).  
Additional Cytokine-Antigen Fusion Proteins 
 While GMCSF-OVA 323-339 fusion protein treatments were chosen for this 
project, other cytokine-antigen products could be considered. IL-16 and IFNβ, for 
example, would be potential candidates for the cytokine domain of a tolerogenic fusion 
protein. IL-16, a chemoattractant for CD4+ immune cells including T Cells, eosinophils, 
dendritic cells, and monocytes, has been implicated in allergic asthma-related IgE 
upregulation and airway hyperresponsiveness (Cruikshank et al., 2000; Hessel et al., 
1998). IFNβ production is downregulated in the asthmatic epithelium and has been 
marketed for use in the treatment of severe asthma symptoms (Holgate et al., 2009). In 
addition, both IL-16 and IFNβ have been shown to be effectually tolerogenic when 
incorporated into fusion proteins in a rat EAE model (Mannie and Abbott, 2007).  
 There are potential candidates for the antigenic domain as well. Of course, if the 
antigenic domain is replaced, then an appropriate model test system that includes 
sensitization to the antigen of choice would have to be utilized. Taking this into account, 
possibilities for antigenic domains within the scope of available murine models would 
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include epitopes from house dust mite or recombinant Blatella germanica 2, a 
cockroach allergen. Due to the size or conformation of the epitopes, successful fusion to 
a cytokine domain may present a challenge, though such epitopes would be particularly 
interesting to incorporate into an antigenic domain for testing in a murine model due to 
their relevance to human allergy. Many other cytokine-antigen fusion combinations 
could be examined in addition to the possibilities listed above, and further exploration 
into various combinations is certainly warranted. 
Fusion Protein Therapy in the Context of Age-related Changes in Asthma 
Future directions and alternatives with regard to the project may also take into 
consideration the impact of aging on therapeutic efficacy, and that certain cytokine-
antigen fusion combinations or doses may affect the aging population differently. Due to 
many age-related changes ranging from cell and tissue function to responsiveness to 
therapeutics, dose and formulation of the cytokine fusion proteins used for treatment 
may not translate for aging populations. Both lung function and immune responses 
decline in older adults, resulting in age-related changes in the manifestation of 
pulmonary diseases (Brand et al., 2011). During the first two decades of life, the lungs 
physically grow, and as lung capacity increases, maximum forced expiratory flow (FEV1) 
and volume (FVC) increase. From birth to adolescence, the lung tissue becomes stiffer 
and elastic recoil increases. Thereafter, lung elastic recoil decreases, and the lungs 
become more flaccid as part of the normal aging process. In addition, with age, alveolar 
ventilation becomes more heterogenous, physicochemical transfer of inspired gas to the 
blood (diffusing capacity) declines, and FEV1 and FVC gradually decline. A variety of 
exogenous factors impact lung function throughout life, causing gradual and cumulative 
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effects that are often not manifest until later life. These factors include exposure to 
environmental and industrial agents, and residual effects of disease. 
The normal decline in lung function is less well tolerated in asthmatic individuals 
who have a lower level of basal function due to chronic disease (Sharma and Goodwin, 
2006; Colebatch et al., 1979; Wahba, 1983). In addition, responsiveness to 
pharmacologic agents changes, altering efficacy of therapeutic agents in the elderly. For 
example, bronchodilator efficacy decreases with age in some individuals as reversible 
bronchoconstriction transitions towards fixed obstruction. Also, Zafirlukast, an oral 
leukotriene receptor antagonist, is less effective in improving lung function with age 
(Hanania et al., 2011).   
Asthma-related inflammation becomes more severe with age, and the 
inflammatory cell profile is altered compared to the younger population (Busse and 
Mathur, 2010). Several factors contribute to this trend, including reduced capacity for 
mucociliary clearance of inhaled pathogens. Ciliary beating and particle clearance 
decreases from adolescence to old age, while production of mucins increases. The 
change in balance between mucus production and clearance increases the propensity 
for airway obstruction. Decreased mucus clearance also increases risk of infection 
(Busse and Mathur, 2010; Lee et al., 2012). 
Immunosenescence that accompanies aging contributes to changes in the 
characteristics of pulmonary inflammation (Vignola et al., 2003). Immunosenescence 
results from somatic mutations and other forms of molecular damage coupled with 
decreased efficiency of DNA repair. Molecular damage affects cytokine expression and 
growth and function of diverse cell types, including epithelial cells, lymphocytes, 
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eosinophils, neutrophils, natural killer cells, macrophages and monocytes (Hanania et 
al., 2011; Busse and Mathur, 2010; Lee et al., 2012; Jones et al., 2011). Neutrophils are 
found in greater abundance in the airways of aging adults, and comparisons of sputum 
reveals elevated neutrophil numbers in older asthmatic subjects, as well as increased 
mediators associated with neutrophilic inflammation including IL-8, neutrophil elastase, 
and matrix metalloproteinase 9. Increased neutrophil elastase in the elderly may 
contribute to diminished recoil observed in the aging lung. Neutrophils from older adults 
also exhibit reduced chemotaxis, phagocytosis and respiratory burst activity, which can 
impact killing and clearance of pathogens from the airways (Busse and Mathur, 2010). 
The contribution of eosinophils to asthma in the elderly is unclear. Eosinophils 
from older human asthmatics have been reported to exhibit decreased superoxide anion 
production. One study with aged mice exposed to antigenic sensitization and challenge 
reported a greater number of eosinophils in bronchoalveolar lavage fluid than in young 
mice, yet the aged mice experienced reduced airway responsiveness. In another study, 
the number of eosinophils in peripheral blood was elevated in aged animals, and the 
elevation correlated with airway hyperresponsiveness to methacholine. These 
discrepancies have not been fully explained at this time (Busse and Mathur, 2010). 
T cell function also is impacted by age. The thymus, the site of early T cell 
development, undergoes involution and atrophies with age. It is currently unknown 
whether thymic involution causes age-dependent losses in cell-mediated immunity 
(Busse and Mathur, 2010; Vignola et al., 2003). The ratio of memory T cells compared 
to naïve T cells also increases as individuals grow older, most likely due to cumulative 
antigenic exposures. Age-dependent losses in T cell function concur with reduced 
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clonotypic diversity of the naïve T cell repertoire, and in some cases, with oligoclonal 
expansions of memory T cells in the elderly. Potential reductions in clonotypic diversity 
may be a reason why certain infectious diseases are much more severe in adulthood.     
Numbers of B cell precursors in bone marrow decrease with age in humans (Lee 
et al., 2012; Vignola et al., 2003). Studies in mice indicate that antibody production is 
unaffected by age, but affinity and avidity of antibodies produced during a primary 
humoral immune response are decreased. It has been proposed that this may be due to 
limited somatic hypermutation, which plays a role in increasing antibody-antigen 
binding. Some of the age-related effects on B cells may be related to age-related 
changes in T cell function, since adoptive transfer of aged T-cells into younger recipient 
mice resulted in reduced B cell activation, expansion, and IgG production (Busse and 
Mathur, 2010).  
Reports have indicated that the numbers of NK cells are increased in older 
adults, whereas the proliferative response of NKT cells is decreases with age, but both 
NK and NKT cells are reported to exhibit lower of cytotoxic capacity with age (Busse 
and Mathur, 2010). NK and NKT cell types are implicated in viral clearance, and 
impaired cytotoxicity and proliferative responses in the case of NKT cells may contribute 
to episodes of asthma induced by viral infection in elderly patients. 
Monocyte and macrophage phagocytosis, chemotaxis, adherence, and antigen 
presentation show little or no difference with age (Busse and Mathur, 2010). TLR 
expression and signaling, and ROI production are reduced, however. Monocytes from 
aged adults, when stimulated through TLR 1/2 heterodimer, exhibit decreased 
production of IL-6 and TNF-α (Vignola et al., 2003). Monocytes from older adults, when 
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differentiated into macrophages in vitro, exhibit decreased TLR3 expression and 
response to virus, as well as less ROI and RNI production upon stimulation with LPS 
(Busse and Mathur, 2010). Given the many age-related changes that take place in 
asthma pathogenesis, perhaps it should be considered that while one cytokine-antigen 
fusion combination or dosing regimen may be effective in younger subjects, the same 
may not yield comparable results in an aging population. 
Conclusion 
In these studies, biologically active GMCSF-OVA 323-339 cytokine fusion 
constructs were successfully generated, the development of a suitable animal model of 
pulmonary inflammation was completed, and the anti-inflammatory properties of 
GMCSF-OVA 323-339 were confirmed in vivo. When tested in the animal model, mice 
given saline prior to sensitization and challenge with OVA 323-339 showed consistent, 
measurable, significant increases in pulmonary inflammation compared to mice that 
received GMCSF-OVA 323-339 pre-treatment prior to sensitization and challenge with 
the OVA peptide and controls that did not undergo challenge with the OVA peptide. 
Mice given saline prior to sensitization and challenge showed eosinophilia in cytospin 
slides for differential cell counts, cellular infiltration and cuffing of the airways in H&E-
stained lung sections, and a light mucus response in the AB-PAS-stained lung sections, 
while mice given GMCSF-OVA 323-339 pre-treatment showed a marked reduction in 
eosinophils, absent or only slight cellular infiltration in lung sections, and no mucus 
secretion. In agreement with differential cell count data and histological findings, mice 
given saline prior to sensitization and challenge showed a significant elevation in IgG1, 
an indicator of TH2 activity in murine models, as well as a significant increase in BAL 
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IFN-γ, which correlated with increases in pro-inflammatory IL-5 and IL-13 as well as 
increased numbers of eosinophils, compared with mice pre-treated with GMCSF-OVA 
323-339. 
Given the anti-inflammatory nature of the GMCSF-OVA 323-339 fusion protein 
observed in these experiments, studies with fusion proteins should be continued in the 
asthma field as well as in other fields involving immune system-based pathologies. 
Cytokine-fusion proteins hold tremendous potential as therapeutic tools, and the many 
cytokine-fusion variations that could be produced and the outcomes of those various 
fusions may be keys to unlock and reverse many immunopathologies. I am hopeful that 
future exploration of the specific targeting and manipulation of existing immunological 
pathways using fusion protein technology will continue to provide insight into these 
processes. 
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